Clinical trial NCT02092324
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Chronic Neutrophilic Leukemia
Sponsor: OHSU Knight Cancer Institute
Start date: 2014-07-08; Completion date: 2020-01-24
Enrollment: 51 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This phase II trial studies how well ruxolitinib phosphate works in treating patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (aCML). Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cells to reproduce. This trial also studies the genetic makeup of patients. Certain genes in cancer cells may determine how the cancer grows or spreads and how it may respond to different drugs. Studying how the genes associated with CNL and aCML respond to the study drug may help doctors learn more about CNL and aCML and improve the treatment for these diseases.

Detailed description:
PRIMARY OBJECTIVES:

I. To determine the proportion of patients with chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) who have a hematologic response to ruxolitinib (ruxolitinib phosphate) (partial response \[PR\], complete response \[CR\], complete response, partial \[CRp\]).

SECONDARY OBJECTIVES:

I. To determine the frequency of grade 3 or 4 hematologic and non-hematologic adverse events experienced by subjects during therapy with ruxolitinib.

II. To determine whether hematologic responses correlate with certain types of mutations in colony stimulating factor 3 receptor (CSF3R) and reduction in mutant CSF3R allele burden in the peripheral blood.

III. To determine the maximum clinical responses for each subject and the median duration of maximum clinical responses.

IV. To determine the mean % reduction of spleen size, estimated by volume using the conventional prolate ellipsoid method as measured by ultrasound compare to baseline.

V. To determine the mean % reduction of total symptom score as measured by a modified Myeloproliferative Neoplasm Symptom Assessment Form version 2.0 (MPN-SAF) compared to start of study (day 1, cycle 1).

VI. To determine overall survival in subjects who complete a minimum of 1 dose of study drug.

VII. To determine the proportion of subjects who discontinue after completion of \> 3 cycles but \< 6 cycles.

VIII. To determine the proportion of subjects who discontinue prior to completion of cycle 3.

OUTLINE:

Patients receive ruxolitinib phosphate orally (PO) every other day, once daily (QD), or twice daily (BID) on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.

After completion of study treatment, patients are followed up within 2 weeks and at 4-6 weeks.

Arms: arm 1: Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
Interventions: intervention 1: Laboratory Biomarker Analysis intervention 2: Quality-of-Life Assessment intervention 3: Questionnaire Administration intervention 4: Ruxolitinib Phosphate
Intervention descriptions: intervention 1: Correlative studies intervention 2: Ancillary studies intervention 3: Ancillary studies intervention 4: Given PO

Protocol documents:
Prot_SAP_000.pdf: 
 
TITLE:  Prospective Evaluation of Ruxolitinib Efficacy for 
CNL/aCML Patients with Mutation of CSF3R 
 
 
ClinicalTrials.gov Identifier: NCT02092324 
 
 
Document date: December 7, 2017 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 1 
 
Oregon Health & Science University 
OHSU Knight Cancer Institute 
OHSU IRB Protocol #: 10262 
Other Protocol #: N/A 
 
TITLE:  Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R 
 
 
 
 
 
 
 
OHSU Principal Investigator:  
Kim-Hien Dao, DO, PhD 
 
Oregon Health & Science University 
 
3181 SW Sam Jackson Park Road 
 
Mail Code: UHN 73C 
 
Portland, OR 97239 
 
 
 
(503) 494-7894 
 
 
 
daok@ohsu.edu 
 
OHSU Co-Investigators: 
 
Jeff Tyner, PhD 
 
 
 
 
 
Oregon Health & Science University 
 
3181 SW Sam Jackson Park Road 
 
Mail Code: L592 
 
Portland, OR 97239 
 
 
 
(503) 346-0603 
 
 
 
tynerj@ohsu.edu 
 
 
 
 
 
 
 
 
Brian Druker, MD 
 
Oregon Health & Science University 
 
3181 SW Sam Jackson Park Road 
 
Mail Code: L592 
 
Portland, OR 97239 
 
 
 
(503) 494-5596 
 
 
 
drukerb@ohsu.edu 
 
 
Statistician: 
 
 
 
Yiyi Chen, PhD 
 
Oregon Health & Science University 
 
3181 SW Sam Jackson Park Road 
 
Mail Code: CR-145 
 
Portland, OR 97239 
 
(503)346-0790 
 
chenyiy@ohsu.edu 
 
OHSU Central Contact: 
 
Oregon Health & Science University 
 
 
 
Center for Hematologic Malignancies 
 
 
 
Knight Cancer Institute- Clinical Research 
 
 
 
3181 SW Sam Jackson Park Road/UHN 73C 
 
 
 
Portland, OR 97239  
 
 
 
503-494-5074 or 503-494-1551 
 
 
 
OHSUCNLRegulatory@ohsu.edu 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 2 
 
Supplied Agent: 
 
Ruxolitinib (IND # 122,092) 
 
 
 
Original Protocol Date: 
April 11, 2014 
Protocol Revision Dates: 
October 6, 2014 
 
January 21, 2016 
 
September 29, 2016 
 
December 20, 2016 
July 25, 2017 
 
Participating Sub Sites:  
 
 
 
Sub Site 
Principal Investigator 
Phone 
Email 
Emory University 
Elliott F Winton, MD 
404-778-4755 
ewinton@emory.edu 
Stanford University Medical 
Center 
Jason Gotlib, MD 
650-736-1253 
 
gotlib@stanford.org 
University of Texas, MD 
Anderson Cancer Center 
Jorge Cortes, MD 
713-794-5783 
jcortes@mdanderson.org 
 
University of Texas, 
Southwestern Medical 
Center 
Robert Collins, MD 
214-648-4155 
robert.collins@utsouthwe
stern.edu 
 
University of Utah, 
Huntsman Cancer Center 
Michael Deininger, 
MD, PhD 
801-213-5684 
 
michael.deininger@hci.ut
ah.edu 
Washington University 
Stephen Oh, MD, PhD 
314-362-8846 
stoh@dom.wustl.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 3 
 
 
 
 
SCHEMA 
Meets criteria for diagnosis of CNL or aCML  
(see Appendix A) 
 
 
 
Screening period 
(up to 4 weeks, see Section 10.1) 
 
 
 
Patients eligible for treatment with ruxolitinib 
(up to 96 weeks, see Section 5.1) 
 
 
 
End of treatment or early discontinuation 
(within 14 days of drug discontinuation, see Section 10.3)  
 
 
 
End of study 
(end of study visit to be completed 4-6 weeks later, see Section 10.4) 
 
Possible options at end of study: 
 
1) Discontinuation of ruxolitinib 
 Optional taper 
 
2) Continue ruxolitinib commercially 
 Patient responsible for obtaining drug through insurer or self-pay 
 
3) Continue ruxolitinib through INCYTE 
 Subject to the sponsor’s approval and/or study extension 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 4 
 
1 
OBJECTIVES ..................................................................................................................... 6 
1.1 
Primary Objectives........................................................................................................ 6 
1.2 
Secondary Objectives.................................................................................................... 6 
2 
BACKGROUND ................................................................................................................ 6 
2.1 
Study Disease ................................................................................................................ 6 
2.2 
Study Agent(s) .............................................................................................................. 7 
2.3 
Other Agent(s) .............................................................................................................. 7 
2.4 
Study and Dose Rationale ............................................................................................. 7 
2.5 
Correlative Studies Background ................................................................................. 10 
3 
STUDY POPULATION ................................................................................................... 10 
3.1 
Inclusion Criteria ........................................................................................................ 10 
3.2 
Exclusion Criteria ....................................................................................................... 11 
4 
REGISTRATION PROCEDURES .................................................................................. 12 
4.1 
Subject Registration .................................................................................................... 12 
5 
TREATMENT PLAN ....................................................................................................... 13 
5.1 
Agent Administration.................................................................................................. 13 
5.2 
General Concomitant Medication and Supportive Care Guidelines ........................... 14 
5.3 
Duration of Treatment................................................................................................. 15 
5.4 
Duration of Follow-up ................................................................................................ 15 
5.5 
Criteria for Removal of a Subject from Study ............................................................ 15 
5.6 
Study Discontinuation ................................................................................................. 16 
6 
DOSING DELAYS/DOSE MODIFICATIONS .............................................................. 16 
7 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ........................... 20 
7.1 
Adverse Events and Potential Risks List(s) ................................................................ 20 
7.2 
Adverse Event Characteristics .................................................................................... 21 
7.3 
OHSU IRB Reporting of Unanticipated Problems and Adverse Events .................... 22 
7.4 
Central Reporting of Adverse Events for Multicenter Studies ................................... 22 
7.5 
MedWatch Reporting .................................................................................................. 22 
7.6 
Sponsor or additional reporting requirements............................................................. 23 
8 
PHARMACEUTICAL and/or IMAGING AGENT INFORMATION ............................ 23 
8.1 
Agent Accountability .................................................................................................. 23 
8.2 
Study Agent(s) ............................................................................................................ 24 
8.3 
Commercial Agent(s) (if applicable) .......................................................................... 24 
9 
BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ....................................... 24 
9.1 
Biomarker Studies ....................................................................................................... 24 
9.2 
Laboratory Correlative Studies ................................................................................... 24 
9.3 
Special Studies ............................................................................................................ 26 
10 
STUDY PROCEDURES AND SCHEDULE OF EVENTS ............................................ 26 
10.1 
Screening/Baseline ...................................................................................................... 26 
10.2 
Study Treatment Visits ............................................................................................... 26 
10.3 
End of Treatment Visit................................................................................................ 26 
10.4 
End of Study Visit ....................................................................................................... 27 
10.5 
Study Assessments and Procedures ............................................................................ 27 
10.6 
Clinical Response........................................................................................................ 30 
10.7 
Schedule of Events ...................................................................................................... 31 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 5 
 
10.6 
Antitumor Effect – Solid Tumors ............................................................................... 35 
10.7 
Antitumor Effect – Hematologic Tumors ................................................................... 35 
10.8 
Other Response Parameters ........................................................................................ 35 
11 
DATA REPORTING/REGULATORY REQUIREMENTS ............................................ 35 
11.1 
Data Collection and Storage ....................................................................................... 35 
11.2 
Multicenter Guidelines................................................................................................ 36 
11.3 
Protocol Review .......................................................................................................... 36 
11.4 
Informed Consent........................................................................................................ 37 
11.5 
Changes to Protocol .................................................................................................... 37 
11.6 
Maintenance of Records ............................................................................................. 37 
11.7 
OHSU IRB Reporting of Unanticipated Problems and Adverse Events .................... 37 
11.8 
OHSU Knight Cancer Institute Data and Safety Monitoring Plan ............................. 37 
11.9 
Inclusion of Women, Minorities and Children ........................................................... 38 
12 
STATISTICAL CONSIDERATIONS.............................................................................. 39 
12.1 
Study Design ............................................................................................................... 39 
12.2 
Primary and Secondary Endpoints .............................................................................. 39 
12.3 
Analysis Populations ................................................................................................... 40 
12.4 
Statistical Analysis Plan .............................................................................................. 41 
12.5 
Sample Size and Power ............................................................................................... 41 
12.6 
Randomization Method ............................................................................................... 41 
12.7 
Handling of Missing Data ........................................................................................... 41 
APPENDIX A Criteria for diagnosis of CNL and aCML ............................................................ 42 
APPENDIX B Summary of starting dose and dose adjustments from prescribing information for 
ruxolitinib ...................................................................................................................................... 43 
APPENDIX C ECOG Performance Status* ................................................................................. 44 
APPENDIX D Table of Moderate and potent CYP3A4 inhibitors .............................................. 45 
APPENDIX E Grading of hemorrhagic events ............................................................................ 46 
APPENDIX F Adverse events and side effects with ruxolitinib .................................................. 47 
APPENDIX G Effective contraceptive practices ......................................................................... 48 
List of Abbreviations .................................................................................................................... 49 
References ..................................................................................................................................... 51 
 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 6 
 
1 
OBJECTIVES   
1.1 
Primary Objectives 
1.1.1 
To determine the proportion of patients with chronic neutrophilic leukemia (CNL) 
and atypical chronic myeloid leukemia (aCML) who have a hematologic response to 
ruxolitinib (PR, CR, CRp).  See table 6 and section 13.2 for specific parameters. 
1.2 
Secondary Objectives 
1.2.1 
To determine the frequency of grade 3 or 4 hematologic and non-hematologic 
adverse events experienced by subjects during therapy with ruxolitinib.  See 
CTCAE reference in Appendix E.   
1.2.2 
To determine whether hematologic responses, as defined in section 13.2, correlate 
with certain types of mutations in CSF3R and reduction in mutant CSF3R allele 
burden in the peripheral blood.                                                                                                                 
1.2.3 
To determine the maximum clinical responses for each subject (defined in Table 6) 
and the median duration of maximum clinical responses. 
1.2.4 
To determine the mean % reduction of spleen size, estimated by volume using the 
conventional prolate ellipsoid method as measured by ultrasound compare to 
baseline. 
1.2.5 
To determine the mean % reduction of total symptom score as measured by a 
modified MPN-SAF (see section 13.2) compared to start of study (day 1, cycle 1). 
1.2.6 
To determine overall survival in subjects who complete a minimum of 1 dose of 
study drug. 
1.2.7 
To determine the proportion of subjects who discontinue after completion of > 3 
cycles but < 6 cycles.  
1.2.8 
To determine the proportion of subjects who discontinue prior to completion of 
cycle 3.     
 
2 
BACKGROUND 
2.1 
Study Disease 
CNL and aCML are both hematologic neoplasms characterized by leukocytosis and hypercellular 
bone marrow comprised predominantly of granulocytic cells, absence of the Philadelphia 
chromosome (t(9;22); BCR-ABL1), and absence of platelet-derived growth factor receptor A/B 
(PDGFRA/B) or fibroblast growth factor receptor 1 (FGFR1) gene rearrangements. CNL is 
diagnosed based on expansion of neutrophils in both the blood and bone marrow (segmented 
neutrophils and band forms > 80% of white blood cells (WBC)) and is classified as a 
myeloproliferative neoplasm (MPN) according to World Health Organization (WHO) diagnostic 
criteria. Cases of aCML exhibit granulocytic dysplasia and increased numbers of neutrophil 
precursors in both the peripheral blood and the bone marrow (typically ≥ 10% of WBCs) and are 
therefore classified as one subtype of the WHO category of myelodysplastic/myeloproliferative 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 7 
 
neoplasms1,2. Occasional cases of CNL3,4 and a majority of aCML cases are reported to exhibit non-
specific cytogenetic abnormalities5 or infrequently the JAK2 V617F mutation6,7, revealing the clonal 
nature of these diseases. While certain MPN subtypes have either been operationally defined by 
molecular abnormalities (e.g. BCR-ABL1 in CML) or are characterized by a high frequency of 
specific genetic abnormalities (e.g. JAK2 V617F in polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis (PMF)6,8-11; KIT D816V in systemic 
mastocytosis12,13), the genetic basis of both CNL and aCML was unknown until recently.  Standard 
of care is not established for CNL and aCML and the estimated median overall survival is 23.5 
months.14 
2.2 
Study Agent(s)  
 
 
Ruxolitinib (Jakafi, INCB018424) is a potent, and selective inhibitor of JAK1 (IC50 = 3.3 ± 1.2 nM) 
and JAK2 (IC50 = 2.8 ± 1.2 nM) with modest to marked selectivity against TYK2 (IC50 = 19 ± 3.2 
nM) and JAK3 (IC50 = 428 ± 243 nM), respectively.  Ruxolitinib was FDA-approved in November 
2011 for treatment of intermediate to high-risk primary myelofibrosis or post-essential 
thrombocytosis (ET) or post-polycythemia vera (PV) myelofibrosis.  More recently, a role for 
ruxolitinib for reducing disease burden in CNL and aCML was identified based on characterization 
of oncogenic CSF3R mutations.15  Ruxolitinib has high solubility and permeability. It is designated 
as a Class I molecule in the Biopharmaceutical Classification System and exhibits moderate-to-high 
clearance, volume of distribution and oral bioavailability in preclinical species.  
 
The pharmacology of ruxolitinib has been studied in both healthy volunteers and patients with 
hematologic and solid tumor malignancies. Ruxolitinib is more than 95% absorbed orally (regardless 
of food ingestion) with peak plasma concentrations occurring 1-2 hours after dosing. (Investigator’s 
Brochure, Edition 11) The pharmacokinetics are linear and there is 97% plasma protein binding with 
limited penetrance across the bloodbrain barrier. The majority of drug is excreted in the urine (75%) 
with less than 1% excreted as unchanged parent drug. The mean terminal half-life is 3-5 hours, and 
it is metabolized through the cytochrome P450 isozyme CYP3A4 resulting in oxygenated and 
conjugative metabolites. Twice daily dosing does not result in significant accumulation of the parent 
compound or its metabolites. The total daily dose should be reduced by 50% when ruxolitinib is 
administered with moderate or potent CYP3A4 inhibitors, but not dose-adjusted when given with 
CYP3A4 inducers.  
 
2.3 
Other Agent(s) 
 
 
Not applicable.  
2.4 
Study and Dose Rationale 
We have identified gain-of-function mutations in the receptor for Colony Stimulating Factor 
3 (CSF3; GCSF), CSF3R, in ~60% of patients with chronic neutrophilic leukemia (CNL) and 
atypical (BCR-ABL-negative) chronic myeloid leukemia (aCML).15  We have also observed these 
mutations in ~1% of AML patients (Table 1).  CSF3R mutations predict for sensitivity of the 
malignant cells to JAK2 inhibition. These data suggest that JAK2 inhibitors, such as ruxolitinib, 
would be beneficial therapeutic agents for the majority of CNL/aCML patients. Demonstration of 
the clinical efficacy of this proposed therapeutic strategy will require a prospective clinical trial 
where CNL and aCML patients are treated with ruxolitinib, and the response of patients harboring 
CSF3R mutations is monitored. 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 8 
 
 
Table 1. Summary of CSF3R 
mutational 
status 
by 
hematologic 
malignancy 
subset reveals enrichment of 
CSF3R mutations in patients 
with CNL and aCML.  CNL – 
Chronic 
Neutrophilic 
Leukemia; aCML – atypical Chronic Myeloid Leukemia, BCR-ABL-negative; AML – Acute 
Myeloid Leukemia; T-ALL – T-cell Acute Lymphoblastic Leukemia; ETP-T-ALL – Early T-cell 
Precursor T-ALL; B-ALL – B-cell Acute Lymphoblastic Leukemia. 
 
CSF3R is the receptor for colony stimulating factor 3 
(CSF3; GCSF), and is thought to play a prominent role in 
the growth and differentiation of granulocytes16,17. CSF3R 
mutations have been described in patients with severe 
congenital neutropenia (SCN), which can evolve into 
acute myeloid leukemia (AML)18-20; it was recently 
reported that an SCN patient developed sequential 
acquisition of a secondary CSF3R mutation at the time of 
AML transformation21. These previously described 
nonsense/frameshift mutations truncate the cytoplasmic 
tail of CSF3R, impair its internalization, and alter its 
interactions with proteins such as SHP-1/2 and SOCS 
family members22-24. These structural and functional 
alterations are thought to perturb the capacity of CSF3R 
to regulate granulocyte differentiation and to increase granulocytic proliferative capacity25-27. 
CSF3R signals through the JAK/STAT pathway, the non-receptor tyrosine kinase SYK28,29, and the 
SRC family kinase (SFK) LYN, which was recently shown to be mediated by the phosphatase SHP-
2 and the adaptor protein GAB228-31. With the exception of isolated case reports32, mutations in 
CSF3R have not previously been observed in cases of de novo leukemia. 
 
The CSF3R mutations that we have identified cluster into two distinct regions of the receptor, 
with the majority occurring just 
extracellular of the transmembrane 
domain 
(membrane 
proximal 
mutations) and a small number 
resulting in truncation of the 
cytoplasmic 
tail 
(truncation 
mutations) (Figure 1).  By far, the 
most prevalent mutations are the 
membrane 
proximal 
mutations 
(T618I and T615A), which result in 
ligand independent activation of 
CSF3R signaling. The dominant 
downstream 
substrate 
in 
this 
context is JAK2. As such, cells harboring membrane proximal CSF3R mutations are exquisitely 
sensitive to ruxolitinib, with IC50s of ~100-200 nM. An index patient with CSF3R T618I-driven 
CNL has been treated with ruxolitinib for ~8 months and still exhibits a dramatic and durable 
Diagnosis 
Mutation 
Estimate of 
Frequency 
CNL/aCML 
16/27 
59% 
AML 
3/292 
~1% 
T-ALL 
0/8 
0 
ETP-T-AL 
1/3 
Unknown 
B-ALL 
0/41 
0 
2 
1 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 9 
 
response with near normalization of white blood cell counts, and complete normalization of other 
blood parameters, including dramatic increases in platelet counts to normal levels (Figure 2). 
 
Finally, although truncation mutations are much less common, data from primary bone marrow 
colony assays suggest that cells harboring truncation mutations of CSF3R may be similarly 
sensitive to ruxolitinib, though these cells are also sensitive to inhibitors of SRC-family kinases 
(Figure 3). 
 
Collectively, these data argue 
strongly 
that 
ruxolitinib 
represents 
a 
promising 
therapeutic for the majority of 
patients with CNL and aCML 
and that these patients may exhibit 
durable, long-term responses to 
ruxolitinib, 
similar 
to 
the 
responses of CML patients to ABL 
kinase 
inhibitors. 
Currently, 
hydroxyurea is the only available 
therapy to control counts and 
symptoms but does little to change 
the natural history of the disease.  
In one report, the estimated median 
overall survival is 23.5 months 
with standard therapy14.  Though 
CNL and aCML are not common forms of hematologic malignancy (estimate of several hundred 
cases per year in the U.S.), the therapeutic benefit may be long-lasting for these patients and could 
convert these diseases into one that patients can live with. 
 
The clinical efficacy results of ruxolitinib in the treatment of myelofibrosis have emerged from the 
ongoing Phase 1 /2 and Phase 3 studies are notable, including marked reduction in splenomegaly, 
improvement in symptoms, performance status and activity level, and reduction in plasma levels 
of inflammatory, prothrombotic and angiogenic cytokines.  The Phase 3 studies have been 
published33 and these results led to FDA approval of ruxolitinib for intermediate to high-risk 
myelofibrosis in November 2011.  In light of the preclinical studies and the identification of CSF3R 
as oncogenic drivers in CNL and aCML,15 this study aims to test whether there is clinical benefit 
(defined in primary and secondary objectives) for treatment of these patients with ruxolitinib.  
 
 
In this study, all subjects with a diagnosis of CNL or aCML will begin ruxolitinib at a total daily 
dose between 5 mg and 40 mg (range from 5 mg qd to 20 mg bid).  The starting dose is based on 
the general dosing guideline provided in the ruxolitinib prescribing information based on platelet 
counts for the treatment of intermediate to high risk myelofibrosis (Appendix B).  Within these 
parameters, we have defined specific doses based on actual start of study (day 1, cycle 1) platelet 
counts and on concomitant drugs categorized as moderate or potent CYP 3A4 inhibitors.   
3 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 10 
 
2.5 
Correlative Studies Background 
2.5.1 
Correlative study: Correlate hematological responses (defined in Table 6 and in 
section 13.2) with ruxolitinib therapy to mutant CSF3R allele burden  
2.5.1.1 
Rationale:  Oncogenic CSF3R drives survival and proliferation of CNL and aCML cells in 
preclinical studies.15  Based on these studies, therapies that specifically inhibit CSF3R or its 
downstream signaling pathways are expected to reduce survival and proliferation of CNL and 
aCML cells.  Ruxolitinib targets JAK1/2 kinase signaling, a downstream signaling pathway of 
CSF3R activation, and is the basis for this clinical trial concept and its predicted efficacy in 
patients. 
2.5.1.2 
Hypothesis:  We hypothesize that in cases of CNL or aCML that harbor mutant CSF3R, the 
mutant allele burden is reduced compared to start of study (day 1, cycle 1) values and correlates 
with hematological responses to ruxolitinib.   
2.5.2 
Correlative study: Identification of novel alternative and cooperating mutations 
2.5.2.1 
Rationale:  Some patients who meet the clinical diagnostic criteria for CNL and aCML do not 
harbor mutations in CSF3R.  These patients may have alternative mutations downstream of 
CSF3R or mutations in a parallel signaling pathway that phenocopies the oncogenic potential of 
CSF3R.  Although we expect that most patients will respond to ruxolitinib, there may be cases of 
primary or secondary resistance to ruxolitinib and these cases represent an opportunity to further 
characterize these alternative and/or cooperating mutations in CNL and aCML.  
2.5.2.2 
Hypothesis:  We hypothesize that the development of CNL and aCML is limited to a few 
oncogenic drivers and the occurrence of primary or secondary resistance to ruxolitinib may 
represent alternative or cooperating mutations that could enhance our effort to study early and 
late steps in the pathogenesis of CNL and aCML.  
3 
STUDY POPULATION 
We plan to enroll approximately 50 subjects in order to achieve an overall of 25 evaluable subjects.   
3.1 
Inclusion Criteria 
          All subjects must meet the following inclusion criteria: 
3.1.1 
Subjects must be newly diagnosed or previously diagnosed with CNL or aCML 
(please refer to Appendix A).  All patients must have a bone marrow biopsy completed 
during the screening or baseline period if one has not been done within 90 days of day 
1, cycle one.  
3.1.2 
Subjects must have platelet count greater than 25,000 per microliter at baseline and at 
the start of study (day 1, cycle 1) visit.   
3.1.3 
Subjects must be able to discontinue any drug treatment aimed at lowering disease 
burden in CNL or aCML.  Subjects should discontinue hydroxyurea to treat 
underlying CNL or aCML disease no later than Day -7 (one week before starting 
ruxolitinib).  For drugs that have more long-lasting effects on the marrow, such as 
thalidomide and its analogs, and interferon, subjects should discontinue these no later 
than Day -28.   


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 11 
 
3.1.4 
Subjects must be willing to accept/continue transfusions to treat low hemoglobin 
levels. 
3.1.5 
Subjects must be 18 years or older, male or female.  
3.1.6 
Subjects must have a life expectancy of > 6 months. 
3.2 
Exclusion Criteria 
Any of the following are causes for exclusion from the study, and must be demonstrated not to be   
present on the day of first dose, C1D1 (historical data for measurements or labs may not be used).   
3.2.1 
Subjects unable to review and sign informed consent form. 
3.2.2 
Females who are pregnant or breastfeeding, and males and females who cannot 
comply with requirements to avoid fathering a child or becoming pregnant. See 
Appendix G. 
3.2.3 
Subjects with known diagnosis of HIV or chronic active Hepatitis B or C. Viral testing 
is not required. Subjects with a history of Hepatitis B and/or C are allowed on trial if 
the virus is undetected at the time of enrollment.  
3.2.4 
Subjects with inadequate liver (ALT/SGPT above 4X ULN or direct bilirubin 4X 
ULN AND the lab abnormalities are felt to be due to underlying liver dysfunction).  
3.2.5 
Subjects with end stage renal function (CrCl<15 mL/min or GFR <15 mL/min) 
regardless of whether hemodialysis is required. 
3.2.6 
Subjects with clinically serious infections requiring ongoing antibiotic therapy. 
3.2.7 
Subjects with severe (immediately life threatening) and recent (occurring within the 
last 3 months) cardiac dysfunction, pulmonary dysfunction, esophageal variceal 
bleeding, hemorrhagic strokes, or intracranial hemorrhage are not eligible for study 
participation. 
3.2.8 
Subjects requiring therapeutic doses of anticoagulation or anti-platelet therapies 
(aspirin above 81mg daily, plavix or similar agents) AND platelet counts are below 
50,000 on two different laboratory evaluations, separated by minimum of two 
weeks. 
3.2.9 
Taking investigational or commercial agents or therapies with the intent to treat the 
subject's malignancy other than those therapies permitted as described in section 5.2 
3.2.10 Subjects with invasive malignancy over the previous 2 years except treated early 
stage carcinomas of the skin, completely resected intraepithelial carcinoma of the 
cervix, and completely resected papillary thyroid and follicular thyroid cancers 
 
3.2.11 Previous allergic reactions to JAK inhibitors or excipients. 
3.2.12 Prior therapy with ruxolitinib or other JAK inhibitors. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 12 
 
3.2.13 Subjects who have had major surgery within 4 weeks prior to entering the study.  
3.2.14 Subjects who are anticipated to receive a transplant within the first 6 months of 
treatment on trial.   
 
4 
REGISTRATION PROCEDURES 
4.1 
Subject Registration 
 
Detailed instructions for subject registration can be found in the separate Study Operations 
Manual. 
 
There is no randomization for treatment.  This is a phase II trial with an intention-to-treat all patients 
who are enrolled in this clinical trial. Potential subjects will be seen by investigators of this study as 
a new patient or consult visit or as a follow-up visit.  Referral of potential subjects to co-investigators 
of this study is made as part of standard of care, with the referring physician seeking advice on the 
diagnosis, evaluation, and/or treatment of CNL or aCML 
 
4.1.1 
Local registration.  
Registrations from all consented subjects must be entered into the Knight  
 
 
Clinical Research Management System (CRMS). Registration of OHSU patients 
will include the minimum of the following: 
o A completed Subject Enrollment Form  
o A completed Eligibility Checklist signed by the investigator 
o Signed  copies of the most recently IRB-approved, informed consent form and 
HIPAA authorization 
4.1.2 
Multicenter Registration  
The OHSU coordinating center study team will manage subject registration.  
Investigators at participating sites will identify eligible subjects and send screening 
materials with source documents that support eligibility to OHSU in real time and 
in accordance with study protocol.  Designated Knight clinical staff must review 
and verify eligibility before the participating site may enroll and treat its subject. 
The OHSU coordinating center team will verify completeness of documents, enter 
registration information into the Knight CRMS, and assign a study 
number/identifier.  The coordinating center will send an email to the participating 
site indicating whether or not the subject is eligible, verify registration, and assign 
a participant number/identifier.    
 
 
 
Registration will include a minimum of the following: 
o A completed Subject Enrollment Form  
o A completed Eligibility Checklist signed by the investigator 
o Signed  copies of the most recently IRB-approved, informed consent form and 
HIPAA authorization 
 
 
 
 
 
 
 
 
 
arise. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 13 
 
5 
TREATMENT PLAN 
5.1 
Agent Administration 
We propose that all subjects with a diagnosis of CNL or aCML (please refer to Appendix A) will be eligible 
for treatment with ruxolitinib on this study.  Initial doses of 5, 10, 15, or 20 mg BID will be administered 
based on platelet counts at the start of study (day 1, cycle 1).  The FDA-approved prescribing information 
for ruxolitinib dosing based on platelet counts is provided as a reference (Appendix B).  However, we have 
made additional suggestions where no specific guidance is provided but maintained the suggestions within 
the parameters outlined in the prescribing information.  We highly suggest adjusting the starting dose if the 
subject is on concomitant CYP 3A4 inhibitors, according to the table below.  However, whenever medically 
possible, we suggest avoiding potent CYP3A4 inhibitors and to consult with the main study site for advice.  
Table 2 (below) serves to advise investigators on the initiation of ruxolitinib on study, but the sponsor and 
site principal investigator may choose to modify the dose based on clinical judgment and consideration of 
any safety issues.  
Table 2: Recommendations for Initiation of Ruxolitinib Dosing Based on Platelet Count  
Platelet count at start of 
study (day 1, cycle 1; per 
microliter) 
No CYP 3A4 
inhibitors†‡ 
Moderate 
CYP 3A4 inhibitors† 
Potent 
CYP 3A4 inhibitors† 
>200,000 
20 mg twice daily 
15 mg twice daily 
10 mg twice daily 
150,000-199,000 
15 mg twice daily 
10 mg twice daily 
5 mg twice daily 
100,000-149,000 
10 mg twice daily 
5 mg twice daily 
5 mg daily 
50,000-99,000 
5 mg twice daily 
5 mg daily 
5 mg every other day 
<50,000 
(but more than 25,000) 
5 mg twice daily 
5 mg daily 
5 mg every other day 
 
† Common drugs listed as CYP 3A4 inhibitors and inducers are provided in Appendix D.  Drugs that are 
weak inhibitors of CYP3A4 or are CYP 3A4 inducers require no dose adjustment for the starting dose but 
the investigators may choose to adjust the dose at their discretion after observing platelet counts.  
 
‡ The suggested starting doses comply within the guideline provided in the ruxolitinib prescribing 
information.  However, the starting doses are further defined for patients who have platelet counts of less 
than 150,000 per microliter.  
For patients already on a stable dose of ruxolitinib, when a moderate or potent CYP3A4 inhibitor is 
to be co-administered during the clinical trial, the dose of ruxolitinib should be reduced by 
approximately 50%. 
 
Treatment will be administered on a planned outpatient basis.  Reported adverse events and potential risks 
associated with ruxolitinib are described in Section 7.  Appropriate dose modifications for ruxolitinib are 
described in Section 6.  Doses should be taken by mouth in the morning and evening, approximately 12 
hours apart, and without regards to food.   
 
Subjects will bring all bottles of unopened, empty, and opened/partially used study drug with them to each 
study visit. Investigative site staff will perform a count of returned pills to assess compliance. Study drug, 
including all bottles of unopened, partially opened or empty bottles will then be returned to research 
pharmacy for storage.   
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 14 
 
5.2 
General Concomitant Medication and Supportive Care Guidelines 
 
CYP3A4 Inhibitors 
 
The principal investigator should be alerted if the subject is taking any agent categorized as a moderate or 
potent CYP3A4 inhibitor (please see Appendix D).  Dose adjustment is not required when ruxolitinib is 
co-administered with rifampin or other CYP3A4 inducers, but these agents should be used with caution in 
combination with ruxolitinib and alternative therapy used if available. Use of moderate or potent 
CYP3A4 inhibitors (Appendix D) is discouraged and investigators should seek other options where 
possible. For patients already on a stable dose of ruxolitinib, when a moderate or potent CYP3A4 
inhibitor is to be co-administered during the clinical trial, the dose of ruxolitinib should be reduced by 
approximately 50% and extra hematology assessments should be instituted for close monitoring of 
platelet levels.   
 
Anticoagulation/Antiplatelet Medications 
 
Anticoagulation is allowed provided that platelet counts are maintained above 50,000 per microliter.  
Medications that are anticoagulants or inhibit platelet function are generally not recommended with the 
exception of a maximal dose of 81 mg a day of aspirin given per physician discretion per standard of care 
and over-the-counter doses of NSAIDs and acetaminophen.   Subjects receiving over-the-counter NSAIDs 
should not exceed the recommended dose and should be encouraged to use gastroprotective agents 
(antacids, H2 antagonists or proton pump inhibitors).   
 
• 
Prohibited Anticoagulation/Antiplatelet:  
             Subjects requiring therapeutic doses of anticoagulation or anti-platelet therapies (aspirin above                       
81mg daily, plavix or similar agents) AND platelet counts are below 50,000 on two different    
laboratory evaluations, separated by minimum of two weeks.  Patients who meet these criteria 
are excluded from the study and are withdrawn from the study if other drug or dosing alternatives 
are not possible or if reduction of ruxolitinib dosing does not improve platelets to over 50,000 
per microliter. 
 
Hematopoietic Growth Factor Receptor Agonists 
 
Hematopoietic growth factor receptor agonists (e.g., erythropoietin (Epo) may be used at Investigator’s 
discretion in certain circumstances based on the clinical indications and risks/benefit considerations as 
described in the NCCN ESA guideline 
(http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf). 
 
• 
Prohibited Growth Factors 
Romiplostim or eltrombopag are not permitted beginning with the Baseline Visit (Day -7)      
through the final dose of ruxolitinib. 
 
Other Prohibited Medications and Measures 
• 
Any prior or concomitant use of a JAK inhibitor other than ruxolitinib. 
• 
Any investigational medication other than the study drugs or any investigational agent 
• 
Use of interferon, thalidomide, busulfan, lenalidomide or anagrelide, or any investigational 
medication used to treat CNL or aCML is not permitted at any time beginning on Day -28 up until 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 15 
 
the time that ruxolitinib therapy is permanently discontinued.  
• 
Hydroxyurea should be discontinued before Day -7 up until the time that  ruxolitinib therapy is 
permanently discontinued.  
5.3 
Duration of Treatment 
In the absence of treatment delays due to adverse events, treatment may continue for 96 weeks or until one 
of the following criteria listed in section 5.6 applies. If there is benefit from the study drug, the patient may 
be eligible to continue on treatment past 96 weeks. If the study drug becomes commercially available for 
the disease indication during the duration of treatment, the study team will help transition the patient to 
commercial drug supply. 
 
 
Table 3:  Indices of Disease Progression 
Parameter 
Signs of disease progression 
White blood 
count 
More than doubling of white blood cell count in the absence of a concurrent acute or 
subacute medical illness.  The white blood cell count is compared to the two most 
recent prior lab values and the white blood cell count change is confirmed on 
another lab draw minimum of 2 weeks apart. 
Blasts 
Evolution to AML, defined by >20% blasts in the peripheral blood or bone marrow 
in the absence of a concurrent acute or subacute medical illness.  The peripheral 
blood or bone marrow findings are confirmed on another lab draw minimum of 2 
weeks apart. 
Splenomegaly 
>25% spleen enlargement compared to baseline.  This can sometimes be appreciated 
by palpation (from the mid-costochondral line) but can also be confirmed by 
ultrasound if spleen growth is suspected.   
5.4 
Duration of Follow-up  
Subjects will be in the treatment phase of the study for maximum of 96 weeks.  Subjects will have an end 
of treatment visit (within 14 days of stopping study drug) and an end of study visit (within 4-6 weeks of 
stopping study drug). Subjects removed from study for unacceptable adverse event(s) will be followed until 
resolution or stabilization of the adverse event whichever is longer.  
5.5 
Criteria for Removal of a Subject from Study 
Subjects may choose to withdraw from the study at any time without penalty of jeopardizing their health 
care or loss of benefits to which the subject is otherwise entitled.  Every reasonable effort should be made 
to determine the reason a subject withdraws prematurely, and this information should be recorded in the 
eCRF. 
 
A subject may be withdrawn from the study, if, in the investigator’s expert medical judgment, the subject 
is non-compliant with the study requirements. Subjects may be withdrawn at the discretion of the Food and 
Drug Administration (FDA) or the investigator. 
 
Subjects must discontinue study drug for the following reasons (investigators will review with the main 
study site appropriateness for continuing or discontinuing subject from study): 
• 
In the Investigator’s medical judgment, further participation would be injurious to the subject’s 
health or well being 
• 
Positive urine pregnancy test, confirmed by positive serum pregnancy (serum human chorionic 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 16 
 
gonadotropin) test results 
• 
Consent for continued study drug treatment is withdrawn by the subject 
• 
Termination of the study by the Sponsor Investigator, local health authority, or IRB 
• 
The subjects exhibits leukemic transformation (as evidenced by bone marrow or peripheral blasts 
>20% persisting for at least 2 consecutive laboratory studies at least 2 weeks apart in the absence 
of clinical circumstances suggesting an exaggerated leukoerythroblastic reaction e.g., sepsis, major 
surgery, trauma, or stress). 
• 
The subjects who meet WBC and spleen criteria for disease progression (Table 3), but do not have 
leukemic transformation, AND is on the maximum dose of ruxolitinib 25mg twice daily for more 
than 2 consecutive months.  For patients who meet the WBC and spleen criteria for disease 
progression but are not on ruxolitinib 25mg twice daily, see section 6, dose increases section. 
Investigator can also assert discretionary clinical benefit not addressing these circumstances. For 
particular situations not addressed here, drug can continue if there is ongoing clinical benefit. 
• 
The subject cannot maintain platelet counts of at least 20,000 per microliter over a given 4 week 
interval at the lowest possible dose of 5 mg every other day 
• 
The subject experiences a recurrence of a Grade 3 or Grade 4 bleeding, and believed to be from the 
same source or etiology AND the subject has a platelet count of less than 50,000 per microliter 
AND subject is on the lowest dose possible of 5mg every other day.  Please see Appendix E for 
grading of hemorrhagic events. 
• 
Subjects requiring therapeutic doses of anticoagulation or anti-platelet therapies (aspirin above 
81mg daily, plavix or similar agents) AND platelet counts are below 50,000 on two different 
laboratory evaluations, separated by minimum of two weeks. 
5.6 
Study Discontinuation 
If a subject is withdrawn from the study: 
o The Coordinating Site must be notified. 
o The reason(s) for withdrawal must be documented in the subject’s medical record and CRF 
o The End-of-treatment/Early Termination visit should be performed within 2 weeks of last dose. 
o    All subjects must be followed for safety until the time of the follow-up evaluation or until study                  
drug related toxicities until resolution or stabilization of the adverse event whichever is longer 
whichever is longer.  
 
If the sponsor investigator or regulatory authority discovers conditions during the study that indicate that 
the study or study site should be terminated, this action may be taken after appropriate consultation with 
the investigators.  The sponsor investigator has the right to terminate the participation of either an individual 
site or the study at any time.  Reasons for terminating the study may include the following:   
• 
Incidence or severity of adverse events in this or other studies indicates a potential health hazard to 
subjects. 
• 
Subject enrollment is unsatisfactory. 
• 
Data recording is inaccurate or incomplete. 
• 
Investigator(s) do not adhere to the protocol or applicable regulatory guidelines in conducting the 
study. 
6 
DOSING DELAYS/DOSE MODIFICATIONS 
Dose Adjustments 
If subjects experience thrombocytopenia with platelet counts less than 20,000 per microliter, ruxolitinib 
dosing should be held until the platelet counts are above 25,000 per microliter.  The restarting dose should 
be as follows (Table 4):  


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 17 
 
 
Table 4: Restarting doses in subjects who experienced toxicity that required ruxolitinib hold 
Subjects with a grade 3 or 4 hemorrhage event must HOLD dosing until further evaluation. 
Ruxolitinib may be continued without hold if bleeding event is deemed ongoing from baseline or 
determined by site PI in consultation with Sponsor to be well controlled and unrelated to 
administration of ruxolitinib.  Subjects will have the option to restart or re-escalate the dose with 
improving platelet counts and the source of the bleeding has resolved.  
 
Table 5 outlines the SUGGESTED approach for any grade 3 or 4 non-hematologic toxicity (refer to 
CTCAE for grading, reference in Appendix E).  The investigators’ assessment of unrelated, possible, and 
definite causality to ruxolitinib guides the degree of dose reduction.  The investigators may choose to 
deviate from this approach or HOLD the study drug, based on safety and other medical considerations.   
Table 5:  Dose Adjustment for Ruxolitinib based on Adverse Event Relationship  
AE, is it related to ruxolitinib? 
Dose at time of AE 
Dose adjustment 
Unrelated 
5 mg twice daily 
No adjustment 
 
10 mg twice daily 
No adjustment 
 
15 mg twice daily 
No adjustment 
 
20 mg twice daily 
No adjustment 
Possible 
5 mg twice daily 
5mg daily or HOLD 
 
10 mg twice daily 
5 mg twice daily 
 
15 mg twice daily 
5 mg in AM; 10mg in PM 
 
20 mg twice daily 
10 mg twice daily 
Definite§, §§ 
5 mg twice daily 
HOLD 
 
10 mg twice daily 
HOLD 
 
15 mg twice daily 
HOLD 
 
20 mg twice daily 
HOLD 
§ If the toxicity was determined to be “definitely” related to ruxolitinib, but at a later time point, the AE is 
NOT determined to be “definitely” related to ruxolitinib, then the patient may restart as if the AE has been 
determined to be “possibly” related or “unrelated” in consultation with Study Principal Investigator or 
designee.   
 
§§ If the toxicity was determined to be “definitely” related to ruxolitnib, and the AE has been resolved 
completely or has resolved to a grade 1 or 2 AE or has resolved to baseline, the investigator, after 
consultation with the Study Principal Investigator or designee, may restart the subject on the study drug at 
a reduced dose or the prior dosing level depending on the variables of the AE and clinical circumstances, 
keeping subject safety at the forefront of all considerations.  The AE is not expected to recur based on the 
investigators’ best clinical judgment and in consultation with the Study Principal Investigator or designee. 
Current Platelet Count 
Maximum Dose When Restarting ruxolitinib 
Treatment 
Greater than or equal to 125 X 109/L 
20 mg twice daily 
Between and including 100 and 124  X 109/L 
20 mg twice daily 
Between  and including 75 and 99  X 109/L 
up to 15 mg twice daily 
Between and including 50 and 74  X 109/L 
up to 10 mg twice daily 
Between and including 25 and 49  X 109/L 
up to 5 mg twice daily 
24  X 109/L or less 
DO NOT RESTART WITHOUT CONSULTING 
WITH SPONSOR-INVESTIGATOR.  


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 18 
 
 
If there has been a new concomitant medication categorized as a moderate or potent CYP3A4 inhibitor 
or there has been an increase in doses of ruxolitinib, the investigator is encouraged to monitor platelet 
counts more frequently around the time of the change or dose adjustment.  Investigators should refer to 
Tables 2 and 4. 
 
Returned oral medication will be evaluated and compared to the amount dispensed and the amount that 
should have been taken by the subject to assess compliance with regimen. If the subject is <90% compliant, 
education on proper dosing will be provided to the subject and documented in source. 
 
Investigators may also decrease the dose for any reason based on their clinical judgment, including a more 
conservative approach based on hematological abnormalities or non-hematologic safety findings.  
 
Dosing must be held if any of the following occur: 
• 
Platelet counts decline below 20,000 per microliter (dosing must be interrupted immediately).   
• 
ANC declines to less than 500 per microliter. 
• 
Ongoing Grade 3 or higher hemorrhage event. Ruxolitinib may be continued without hold if 
bleeding event is deemed ongoing from baseline or determined by site PI in consultation with 
Sponsor to be well controlled and unrelated to administration of ruxolitinib.  
 
Dose Increases 
 
Dose increases are optional and are at the discretion of the investigator. The investigator should refer to the 
prescribing information for ruxolitinib (Appendix B) and Table 2 (Section 5.1) as a general guideline based 
on platelet counts and concomitant moderate and potent CYP3A4 inhibitors.  Dose increases of 5mg daily 
or twice daily increments and no more frequent than every 4 weeks are suggested. Subjects who have had 
a sub-therapeutic response (i.e., less than 25% reduction in white blood cells counts and absolute neutrophil 
counts) can have their dose increased to 25mg BID.  For most patients, the maximal dose will be 20 mg 
BID, however, in some instances patients may receive 25 mg BID if the patient has demonstrated a positive, 
but partial response at 20 mg BID in the absence of a dose-limiting toxicity. The investigator will monitor 
platelet counts around the time of the change or dose adjustment per standard of care.   
 
Note that when a 5 mg qd increment is added, creating a regimen such as 5 mg/10 mg, it is suggested that 
the higher dose should be taken in the evening and the lower dose in the morning. 
 
No dose adjustment is recommended when ruxolitinib is co-administered with a CYP3A4 inducer.  
Patients should be closely monitored and the dose titrated based on safety and efficacy. 
 
For subjects not on the maximum dose allowed for the study (ruxolitinib 25mg twice daily) but meets the 
WBC and splenomegaly criteria (table 3) for disease progression, the investigator may increase the dose 
of ruxolitinib up to the maximum tolerated dose or maximum dose allowed for the study (subjects must 
maintain platelet counts greater than 20,000 per microliter, section 5.5).  The coordinating center will 
review the source data and provide suggestions to subsite investigators on dosing.   
 
The subject may stay on study if the WBC (>50% reduction) OR spleen size (>25% reduction by 
ultrasound) is reduced after the subject is either on the maximum tolerated dose or the maximum dose 
allowed for the study for 2 consecutive months.  There is still a perceived clinical benefit to stay on study 
and stay on drug if only the WBC or the spleen size is controlled.     
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 19 
 
Restarting ruxolitinib after Recovery of Platelet or ANC Levels or Resolution of Hemorrhage 
• 
Note that the restarting doses should be reduced by at least 5mg twice daily from what the subject 
was on at the time of the platelet or ANC level or hemorrhagic event that warranted dose 
interruption. 
• 
When dosing is held for ANC decline to less than 500 per microliter, dosing may be restarted when 
ANC is greater than 1,500 per microliter.  
• 
For Grade 2 hemorrhage events of any causality (Appendix E), dosing may be restarted at the prior 
level once the event is resolved to Grade 0, and its underlying cause has been alleviated or resolved, 
as long as platelet count and ANC do not preclude a restart at that dose level.   
• 
For Grade 3 or 4 hemorrhage events of any causality (Appendix E, requires a mandatory dose 
interruption), dosing may only be restarted provided: platelet count >20,000 per microliter and 
ANC >1,000 per microliter, the event has resolved to Grade 0, and the underlying cause has been 
alleviated or resolved, and following discussion with the Study Principal Investigator or designee 
taking into account causality, resolution of the bleeding and underlying etiology and likelihood of 
recurrence, in order to reach agreement that the potential benefits of a restart at an appropriate dose 
outweigh risks of recurrent hemorrhage.  Re-escalation by 5mg daily or twice daily increments and 
no more frequent than every 4 weeks are suggested.  Investigators should exercise caution and 
closely monitor platelet counts around the time of the change or dose adjustment.  
  
Use of Platelet Transfusions 
Platelet transfusions may be used at Investigator’s discretion to treat thrombocytopenia. Dosing restart or 
increase decisions may not be based on platelet count values observed within 7 days of a platelet transfusion. 
 
Management of Anemia 
Subjects with a hemoglobin level < 6.5 g/dL must receive red cell transfusion(s) to maintain a level of ≥ 
6.5 g/dL. Erythropoietin (EPO) use is strongly discouraged, but is permitted at the Investigator’s discretion 
in consultation with the Study Principal Investigator or designee, although use is not permitted in lieu of 
transfusions for hemoglobin below 6.5 g/dL. 
 
Optional Dose Tapering Strategy for Any Reason (medical indication, withdrawal from study, end 
of study, etc.) 
In ongoing clinical studies with ruxolitinib, rapid return of constitutional symptoms and spleen growth has 
been observed in subjects after drug discontinuation.  When a decision is made to permanently discontinue 
ruxolitinib therapy for reasons other than low platelet counts or ANC levels, tapering of ruxolitinib dosage 
may be considered, based on evaluation of the condition of the subject, current dose regimen and the clinical 
judgment of the investigator. Investigators may institute a tapering regimen according to what seems 
medically appropriate.  Doses of ruxolitinib may be very slowly lowered until the subject is completely off 
drug.  If medically indicated, doses of ruxolitinib may be temporarily restarted after they have been 
discontinued. If considered to be medically necessary, the investigator may use any treatment to manage 
withdrawal from ruxolitinib including, but not limited to, the management of events which may be 
secondary to discontinuation, and interruption or reduction of dose administered of ruxolitinib. Short-term 
courses of high-dose corticosteroids, equivalent to doses of > 10 mg/day of prednisolone have been used to 
moderate the withdrawal of ruxolitinib and may be considered as part of a tapering strategy. Corticosteroids 
may be started prior to, or concurrent with, ruxolitinib tapering in anticipation of the possibility of 
occurrence of withdrawal symptoms. When a decision has been made to discontinue the subject with 
utilization of a tapering strategy, regardless of the use of concomitant medications, safety data will continue 
to be assessed in accordance with the protocol.  An End of treatment and subsequent Follow-up Visit must 
be scheduled. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 20 
 
 
Procedures for Interruption of Study medication 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of adverse 
experiences that may have an unclear relationship to study drug.  Refer to Table 5.  The investigator is 
encouraged to consult with the Study Principal Investigator or designee for reasons other than protocol 
mandated medication holds for platelet or ANC counts.  Any AE grade 3 or higher and RELATED to 
ruxolitinib requires mandatory reporting to the OHSU coordinating site within 24 hours of the site’s 
knowledge of the event.  Additionally, the investigator must notify the OHSU coordinating site via email 
before restarting study drug that was temporarily discontinued for an AE. 
 
Procedures for Permanent Discontinuation of Study Drug 
In the event that any subject discontinues the study drug and subsequently withdraws from the study prior 
to completion, regardless of reason, reasonable efforts should be made to have the subject return for an 
Early Termination visit and have the End-of-treatment procedures completed as described in Section 10. 
 
The date the subject discontinued the study drug and the specific reason for discontinuation will be 
recorded. This will include reasons such as discontinuation due to treatment failure or withdrawn due to 
adverse event. This information will be used to summarize the reasons for study discontinuation and 
treatment failure. 
7 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial. The following list of 
AEs (Section 7.1) and the characteristics of an observed AE (Section 7.2) will determine whether the event 
requires expedited reporting.  
 
All AEs grade 3 and greater and all SAEs, regardless of grade, will be recorded in the CRF.  
7.1 
Adverse Events and Potential Risks List(s)  
Potential Risks: 
No specific findings in nonclinical repeat dose toxicity studies identify clinical risks other than noting that 
consequences of immunosuppression may occur. Hypotension and increases in heart rate were noted at a 
high dose in a cardiovascular preclinical study. However, these findings have not been recapitulated in a 
clinical setting. 
 
The primary clinical risks with ruxolitinib treatment are the potential sequelae of decreased hematopoietic 
proliferation secondary to the inhibition of growth factor pathways by JAK2 inhibition. Appendix F lists 
the most common adverse effects.  Dose-dependent, reversible thrombocytopenia has been observed in 
subjects with MF and represents the DLT. The risk of spontaneous hemorrhage in patients as a result of 
thrombocytopenia generally does not become manifest until platelet counts fall below 10,000 per microliter 
(Slichter, 2004); platelet counts below 25,000 per microliter (Grade 4) were not observed in any subjects 
initiating ruxolitinib at starting doses of 10 mg bid or 15 mg bid in the ongoing phase 1 /2 study. In the 
current study, dosing must be interrupted for platelet count below 20,000 per microliter, or for grade 3 or 4 
hemorrhage event. 
 
Anemia and, rarely, neutropenia have also been observed in patients with MF treated with ruxolitinib. 
Increased rates of infection and anemia are potential risks of myelosuppression, and there are multiple 
sequelae of anemia including the burden and risks of transfusion. A few subjects have had an apparent 
worsening of their pre-morbid disease symptoms following rapid cessation of ruxolitinib therapy and a 
gradual tapering and use of steroids in fragile subjects may be considered when stopping ruxolitinib therapy. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 21 
 
7.2 
Adverse Event Characteristics  
CTCAE term (AE description) and grade:  The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.  
All appropriate treatment areas should have access to a copy of the CTCAE version 4.0.  A copy of the 
CTCAE version 4.0 can be downloaded from the CTEP web site: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.   
Expectedness: Adverse Events can be ‘Unexpected’ or ‘Expected’ (see Section 7.1 above for expected 
AEs) based on available safety data.   
Attribution of the AE: 
− 
Definite – the AE is clearly related to the study treatment. 
− 
Probable – the AE is likely related to the study treatment.  
− 
Possible – the AE may be related to the study treatment. 
− 
Unlikely – the AE is unlikely related to the study treatment, but a causal relation cannot be 
 
completely excluded. 
− 
Unrelated – the AE is clearly NOT related to the study treatment. 
7.2.1 
Adverse Event (AE) 
An adverse event (AE) is any undesirable sign, symptom or medical condition or experience that 
develops or worsens in severity after starting the first dose of study treatment or any procedure 
specified in the protocol, even if the event is not considered to be related to the study. Abnormal 
laboratory values or diagnostic test results constitute adverse events only if they induce clinical 
signs or symptoms or require treatment or further diagnostic tests.  
7.2.2 
Serious adverse event (SAE) 
A serious adverse event (SAE) is any adverse event, occurring at any dose and regardless of 
causality that:  
• 
Results in death 
• 
Is life-threatening. Life-threatening means that the person was at immediate risk 
of death from the reaction as it occurred, i.e., it does not include a reaction which 
hypothetically might have caused death had it occurred in a more severe form. 
• 
Requires or prolongs inpatient hospitalization (i.e., the event required at least a 24-
hour hospitalization or prolonged a hospitalization beyond the expected length of 
stay). Hospitalization admissions and/or surgical operations scheduled to occur 
during the study period, but planned prior to study entry are not considered SAEs 
if the illness or disease existed before the person was enrolled in the trial, provided 
that it did not deteriorate in an unexpected manner during the trial (e.g., surgery 
performed earlier than planned). 
• 
Results in persistent or significant disability/incapacity. Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions. 
• 
Is a congenital anomaly or birth defect; or 
• 
Is an important medical event when, based upon appropriate medical judgment, it 
may jeopardize the participant and require medical or surgical intervention to 
prevent one of the outcomes listed above. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at 
home; blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse. 
 
Events not considered to be serious adverse events are hospitalizations for: 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 22 
 
• 
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition, or for elective procedures. 
• 
Elective or pre-planned treatment for a pre-existing condition that did not worsen. 
• 
Emergency outpatient treatment for an event not fulfilling the serious criteria 
outlined above and not resulting in inpatient admission. 
• 
Respite care. 
 
7.3 
OHSU IRB Reporting of Unanticipated Problems and Adverse Events 
Unanticipated Problems (UP) and Adverse Events (AE) will be reported to OHSU IRB according to the 
policies, procedures and guidelines posted on the OHSU IRB web site: 
http://www.ohsu.edu/research/rda/irb/policies.shtml. 
 
Fatal and life-threatening events must be reported to OHSU IRB within 7 calendar days  after the OHSU 
Study PI learns of the event.  If any of these require a change (as determined by the PI or the IRB) to the 
protocol or consent form, the PI will make those changes promptly and submit the revised documents to 
the OHSU IRB. 
 
 
All other UP reports will be submitted to OHSU IRB no later than 15 calendar days of notification of the 
event.  If the event requires changes as determined by the PI or the IRB) to the protocol or consent form, 
the PI will make the changes promptly and submit the revised documents to the IRB.  UP and AE reports 
are submitted through OHSU e-IRB and will be reviewed by OHSU IRB.   
7.4 
Central Reporting of Adverse Events for Multicenter Studies  
The SAE/UP reporting for multicenter investigator initiated clinical trials  will 
follow 
the 
guidelines 
outlined in the OHSU Knight Cancer Institute Multi-Center Investigator Initiated Trials Coordinating 
Center Operations Manual.  
 
A participating site must report an SAE to the to the institution’s local IRB for action as required, as well 
as to the OHSU coordinating center study team by phone, fax, or email within 24 hours of learning of the 
event. The participating center will send the coordinating center materials regarding the SAE including 
pertinent progress notes, hospital admission and discharge notes, laboratory and radiographic studies, and 
the investigators’ assessment and report of the SAE. 
 
The OHSU coordinating center study team will review and submit SAEs to the FDA, OHSU IRB, and any 
other required contacts as required by the Knight Data Safety Monitoring Plan, OHSU IRB policy and/or 
federal regulations. The principal investigator at the OHSU Coordinating Center is responsible for 
distributing IND Action Letters or Safety Reports, as applicable, to participating institutions for review and 
submission to their institution’s local IRB. 
7.5 
MedWatch Reporting  
 
For this investigator-initiated study, the OHSU Principal Investigator is the study sponsor. The sponsor-
investigator is required to report adverse experiences to the FDA through the MedWatch reporting program, 
even if the trial involves a commercially available agent. Adverse experiences to be reported include any 
unexpected (not listed in the package label), serious adverse experiences with a suspected association to the 
study drug.  Adverse events that occur during clinical studies are to be reported to FDA as specified in the 
investigational new drug/biologic regulations using the  FDA 3500 Voluntary Reporting form, which is 
available for submission online at: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm085568.htm 
and is also available as a .pdf.  


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 23 
 
 
Sub sites will report all serious adverse events to the study sponsor within 24 hours of knowledge of the 
event via the OHSU study-specific Safety Reporting Form, along with supporting materials. The sponsor 
will review the submitted SAE report and supporting documentation and submit to the FDA after review. 
Copies of the MedWatch 3500 form and formal safety report notification will be submitted to each sub site 
and OHSU IRB, when appropriate.  A copy of the MedWatch 3500 form, supporting materials and 
documentation of site PI review will be kept on file in the study regulatory binder. The OHSU Coordinating 
Center is responsible for meeting the MedWatch reporting requirements for the study.  
7.6 
Sponsor or additional reporting requirements 
 
 
Unexpected fatal or life-threatening experiences associated with the use of the study treatment will be 
reported to FDA as soon as possible but in no event later than 7 calendar days after initial receipt of the 
information. 
 
All other serious unexpected experiences associated with the use of the study treatment will be reported to 
FDA as soon as possible but in no event later than 15 calendar days after initial receipt of the information. 
 
 
 
Events will be reported to the FDA by submission online using FDA Form 3500 (Voluntary Reporting 
Form for commercial agents).   
 
All events reported to the FDA will also be reported to Incyte Pharmacovigilance representative as provided 
in the Research Agreement within 24 hours of reporting. A copy of the FDA report will also be faxed to 
the Incyte Pharmacovigilance representative. 
8 
PHARMACEUTICAL AND/OR IMAGING AGENT INFORMATION 
 
A list of the adverse events and potential risks associated with the investigational or commercial agents 
administered in this study can be found in Section 7.1 and in Appendix F. 
8.1 
Agent Accountability 
The Investigator, or a responsible party designated by the Investigator at each site, must maintain  
a careful record of the inventory and disposition of the study agent.  (See the NCI Investigator’s Handbook 
for Procedures for Drug Accountability and Storage).  
 
 
http://ctep.cancer.gov/investigatorResources/investigators_handbook.htm 
  
Responsibility for drug accountability at the study site rests with the Investigator; however, the Investigator 
may assign some of the drug accountability duties to an appropriate pharmacist or designee. Inventory and 
accountability records must be maintained and readily available for inspection by the study monitor and are 
open to inspection at any time by any applicable regulatory authorities. 
 
The Investigator or designee will be expected to collect and retain all used, unused, and partially used 
containers of study medication until the end of the study. The Investigator or designee must maintain 
records that document: 
• 
investigational product delivery to the study site 
• 
the inventory at the site 
• 
use by each subject including pill/unit counts from each supply dispensed 
• 
return to the Investigator or designee 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 24 
 
These records should include dates, quantities, batch/serial numbers (if available), and the unique code 
numbers (if available) assigned to the investigational product and study subjects. 
 
The investigational product must be used only in accordance with the protocol. The Investigator will also 
maintain records adequately documenting that the subjects were provided the correct study medication 
specified. 
 
Completed accountability records will be archived by the site. At the completion of the study, the 
Investigator or designee will oversee shipment of any remaining study drug back to Incyte for destruction 
according to institutional standard operating procedures. If local procedures mandate site destruction of 
investigational supply, prior written approval must be obtained from Incyte or Incyte’s study drug 
distributor. 
 
Please refer to the Pharmacy Manual located in the separate Study Operations Manual for details on 
drug supply, ordering and shipment process. 
8.2 
Study Agent(s)  
Availability: Ruxolitinib will be provided by Incyte Corporation and shipped directly to each site by Incyte 
or its distributor.  Each site will be responsible for contacting Incyte or its distributor for study drug supply. 
Route of administration:  Doses should be taken by mouth in the morning and evening, approximately 12 
hours apart, and without regards to food. 
Study Drug Packaging, Labeling and Preparation:  Ruxolitinib Phosphate tablets will be provided as 5 
mg tablets packaged as 60 count in high-density polyethylene bottles.  All bottles of Incyte investigational 
product contain the following language: “Caution: New Drug—Limited by Federal law to investigational 
use.” 
Incyte will be responsible for quality and stability of the drug for shipment to sites. Incyte will also 
communicate any information related to manufacturing issues and expiration dates for each site’s shipment. 
Study Drug Storage and Stability:  The bottles of tablets should be stored at room temperature, 15°C to 
30°C (59°F to 86°F).  Stability studies will be conducted on clinical batches to support the clinical trial. 
8.3 
Commercial Agent(s) (if applicable) 
 Not applicable. 
9 
BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES 
We will determine the mutational status of CSF3R, the mutation type of CSF3R, and the CSF3R mutant 
allele frequency. We will correlate these findings with patient clinical responses. 
 
Refer to the lab manual located in the separate Study Operations Manual 
9.1 
Biomarker Studies 
Not applicable. 
9.2 
Laboratory Correlative Studies 
Whole exome sequencing will be performed on genomic DNA isolated from patient peripheral blood, bone 
marrow specimens as well as germline skin biopsy specimens that are collected upon enrolment of patients 
on this trial. This will provide both qualitative and quantitative assessment of CSF3R and JAK2 mutational 
status as well as identification of other cooperating mutations such as SETBP134. In addition, specimens 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 25 
 
from any patients exhibiting a clinical response, followed by relapse will be re-sequenced (whole exome) 
to understand genetic contributions to drug resistance. In this manner, we will be able to study possible 
mechanisms of primary resistance (from initial whole exome sequencing) as well as secondary resistance 
(whole exome sequencing of relapse specimens). Overall, this will involve whole exome sequencing of 
both pre-treatment and post-treatment specimens in subjects with a response to treatment and only pre-
treatment sequencing in non-respondents who discontinue study prior to primary endpoint (estimate for 
relapse based on experience of ABL inhibitors in CML; germline from enrolment specimen can be used to 
filter relapse specimens). Finally, genomic DNA from all CSF3R-mutant enrolment and follow-up bone 
marrow specimens will be analyzed to assess CSF3R mutation allele frequency using a customized ion 
torrent CSF3R assay, as discussed below in Section 9.3. Special Studies. 
 
After testing exome sequencing is performed and the subject has consented to the storage of samples for 
this study, remaining materials will be stored in a biorepository for future research. The excess sample will 
be processed and stored in the OHSU laboratory, which is an NCI-approved biorepository (OHSU eIRB# 
7267). The repository, which includes banked samples from participants with acute leukemia (AL), 
lymphoproliferative disorders (LPD), myelodysplastic syndrome (MDS), and myeloproliferative diseases 
(MPD). A primary goal of this repository is to store samples from patients with hematologic malignancies 
that can be made available to researchers at OHSU, the collaborating institutions, and commercial 
laboratories. 
 
The biorepository will include de-identified, coded samples from subjects who consented to have their 
samples banked on this study; de-identified samples such as those from other institutions and cord blood 
samples, and “medical waste” samples such as left-over samples from the OHSU Clinical Flow Cytometry 
Laboratory and Clinical Leukapheresis Unit.  
 
Coded, de-identified samples will be processed and frozen in liquid nitrogen freezers. Currently, the 
repository has a capacity of 17,000 samples. The number of stored vials per sample, the type of processing 
they received, and their location in the freezer will be included in the AL, LPD, MDS, and MPD database. 
When a sample is removed, the person who removed it and the destination are recorded in the database. 
The freezer will remain locked when not being accessed.  
 
Stored patient samples are a limited and valuable resource. To assure their best possible use, requests for 
samples will be reviewed for scientific merit and IRB compliance. The group assembled to review sample 
requests will include the study PI as well as OHSU pathologists/oncologists and co-investigators. Coded 
samples and the key linking patient identifiers to clinical data will be released to OHSU investigators 
following group review and IRB approval from OHSU and the institution from which they were received. 
Only coded clinical information will be released. 
 
Samples may also be released to commercial laboratories. These samples will be de-identified and protected 
information will not be released.  


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 26 
 
9.3 
Special Studies 
9.3.1 Determination of CSF3R Mutation Allele Frequency 
9.3.1.1 
We will measure the percentage of CSF3R ion torrent reads that are wild-type versus 
mutant. 
9.3.1.2 
Assessment 
9.3.1.2.1 
Method of Assessment 
9.3.1.2.2 
Allelic burden will be assessed on bone marrow specimens taken at study 
enrolment and again on bone marrow specimens taken at the 6-month 
interval. 
9.3.1.3 
Data Recording 
9.3.1.3.1 
Data will be recorded in the relational database that will be used to track 
specimens and all correlative data (see Section 12). 
9.3.1.3.2 
Data will be recorded upon performance of the assay.  
10 STUDY PROCEDURES AND SCHEDULE OF EVENTS 
10.1 Screening/Baseline 
Screening and Baseline visit procedures can be combined in one visit or performed on more than one visit 
and will be completed within 4 weeks of Cycle 1 Day 1. Refer to Section 10.5 and 10.7 for more detailed 
description of study procedures. The coordinating center must review subject source data for verification 
of inclusion/exclusion criteria prior to subjects receiving drug on trial. Refer to the Study Operations 
Manual for specific enrollment instructions.   
10.2 Study Treatment Visits 
Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long).  If the study 
drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles. If a 
patient continues on study drug past 24 cycles, standard of care visits and standard of care labs will be 
collected every 8 weeks.  In addition, research data will be collected for the post-24 cycles extension period. 
If the study drug becomes commercially available for the disease indication during the duration of 
treatment, the study team will help transition the patient to commercial drug supply. There is no established 
standard of care for CNL and aCML.  The schedule lists the mandatory data collected at each time point 
for the clinical trial but it is expected that additional tests/procedures or visits may occur as standard of care, 
which is entirely at the discretion of the investigator. Most patients will have additional laboratory studies 
and clinical evaluations outside of this schedule as part of their standard of care.  Frequent monitoring is 
suggested for patients who have severe anemia or thrombocytopenia (for example, Hgb <7 g/dL and platelet 
counts <30,000 per microliter).  The labs or studies outlined in section 10.8 schedule of events may be 
completed within 7 days of the target week (7 days before or 7 days after).  However, every effort will be 
made to adhere to this schedule as close as possible.  This is the minimum schedule of laboratory studies 
and follow-up visits required for the study 
10.3 End of Treatment Visit 
Subjects will be evaluated during Week 4 of Cycle 24 for end of treatment or within 2 weeks after 
stopping study drug. Every attempt will be made to devise a treatment plan weeks before the patient stops 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 27 
 
the study drug.  In those patients that withdraw from the study abruptly for any reason, a standard of care 
treatment plan will be formulated as soon as possible.  Subject should be encouraged to return for the 
follow-up visit. Subjects will have the option to taper off ruxolitinib or go on commercial ruxolitinib 
therapy especially if there is a documented clinical benefit.  See section 6.0 regarding approach for 
tapering ruxolitinib.   
10.4 End of Study Visit  
Subjects will be evaluated 4-6 weeks after stopping study drug for a safety evaluation. Reasonable efforts 
should be made to have the subject return for the follow up visit. Every attempt will be made to devise a 
treatment plan weeks before the patient stops the study drug.  In those patients that withdraw from the 
study abruptly for any reason, a standard of care treatment plan will be formulated as soon as possible.  
Subjects will have the option to taper off ruxolitinib or go on commercial ruxolitinib therapy especially if 
there is a documented clinical benefit.  See section 6.0 regarding approach for tapering ruxolitinib.   
10.5 Study Assessments and Procedures 
 
Dose adjustments or the occurrence of hematologic or non-hematologic grade 3 or 4 adverse events will 
require additional clinical evaluations and/or laboratory studies but should not be any less frequent than the 
schedule outlined. 
• 
Demographics and Medical History:  Demographic data and a complete medical history will be 
collected at visits prior to starting study treatment. Medical history in between visits should be 
documented at each study visit once study treatment has started. All transfusions including date, product 
transfused, number of units, and reason for transfusion should also be collected as part of the interval 
medical history.  
 
• 
Concomitant Medications:  All concomitant medications and treatments must be recorded in the case 
report form (CRF).  Any prior medication received up to 30 days prior to the Baseline visit will be 
recorded in the CRF. Concomitant treatments that are required to manage a subject’s medical condition 
during the study will also be recorded in the CRF. Prior and/ or ongoing medications will be reviewed 
during screening to determine subject eligibility. The medication record will be maintained following 
enrollment including any changes to the dose or regimen. Prior and concomitant medication including 
any prescription, over the counter or natural/herbal/multivitamin preparations taken will be recorded.  
 
• 
Physical Exam:  Physical exams must be performed by a medially qualified individual such as a 
licensed physician, Physician’s Assistant or advanced Registered Nurse Practitioner as local law 
permits. The physical exam at baseline should include the following organ or body systems per 
institutional standards: skin, head, eyes, ears, nose, throat, thyroid, lungs, cardiovascular, abdomen, 
extremities, lymph nodes. All other physical exams will include an evaluation of any AEs or any 
previously reported symptoms or prior physical examination findings. 
Physical Exam must include an IPSS score at each time point as described in the Schedule of Events 
(one point for each criteria, maximum of 5 points total): 
 Age >65 y/o 
 Hgb <10 g/dL 
 Leukocytosis >25,000 per microliter 
 Peripheral blasts > or = 1% 
 Weight loss of >10% of average adult weight prior to leukemia diagnosis, or presence of 
disease-related night sweats or fevers 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 28 
 
• 
Performance Status:  ECOG will be determined and performed at the visits indicated in the schedule 
of events in section 10.8. Refer to Appendix C for ECOG scale. 
 
• 
Pregnancy Test:  A urine pregnancy test is required for all female subjects during screening for women 
of childbearing potential. If the urine pregnancy test is positive, serum pregnancy tests must be 
performed per institutional standards.  
 
• 
Weight:  Must be collected at each study visit 
 
• 
Height:  Must be collected prior to day of study treatment.  
 
• 
Vital Signs:  Vital sign measurements should be taken per institutional standards at each study visit.  
 
• 
Complete Blood Count:  Local hematology will be collected per institutional standard of care and 
must include an extended differential, hematocrit and MCV. The exact values of the extended 
differential profile is per local institutional standard of care. 
 
• 
Coagulation panel: INR/PT and aPTT are required. 
• 
Chemistry:  Local chemistry will be collected per institutional standards and must include LDH and 
uric acid.  
 
• 
Spleen size:  In this study, spleen size is only estimated by ultrasound (limited ultrasound or full 
ultrasound per standard of care) at the mandatory time points as indicated in the schedule of events. 
Spleen volume will be calculated by the conventional prolate ellipsoid method. Measure spleen width, 
thickness and maximum length in centimetres. Multiply width by thickness by max length by 0.524 to 
get the total spleen volume in cm3. The longest dimension (centimetres) in the cranio-caudal axis is 
also recorded.  A percentage of change will be calculated at the mandatory time points as indicated in 
the schedule of events in cases when only 2 dimensions are available. Studies completed within 2 
months of start of drug date are acceptable for baseline evaluation. Additional ultrasounds may be 
completed during the study per investigator discretion.  Beyond the mandatory ultrasounds to 
estimate spleen size, Investigators should estimate spleen response by palpation as part of the physical 
exam throughout the study and can be recorded in the clinical evaluation and in Medidata..  If the 
clinical assessment suggests disease progression ( refer to table 3), the investigator will perform 
repeat labs, bone marrow evaluation, and ultrasound of the spleen as part of standard of care to 
confirm  the presence or absence of suspected disease progression. 
 
• 
Bone Marrow Exam:  A bone marrow exam aspirate must be collected at the visits outlined in the 
Schedule of Events and include the elements listed below per standard of care. Additional bone 
marrow evaluations may occur if clinically indicated at the discretion of the investigator, e.g., at the 
time of suspected disease progression or disease remission. An independent hematopathologist(s) not 
involved in the study will adjudicate availablebone marrow biopsy slides to enhance the assignment 
of the diagnostic category for each subject given some existing arbitrary or ill-defined WHO criteria.   
 
If a bone marrow exam has been done within the last 90 days, the actual slides and the 
hematopathology report may be reviewed and used in place of repeating a bone marrow 
evaluation so long as the studies described below have been performed and the sample is of 
sufficient quality for interpretation. Investigators from other sites may consult with the 
coordinating center (OHSU Coordinating Center) if necessary to help make this determination. 
 
Bone Marrow requirements:  


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 29 
 
o Hematopathology  
o Cellularity % 
o Blasts %, by morphology 
o CD34+ blasts by immunohistochemistry staining %, if collected as standard of 
care per institutional standards 
o Degree of granulocytic hyperplasia %, if collected as standard of care per 
institutional standards 
o Degree of granulocytic dysplasia %, if collected as standard of care per 
institutional standards 
o Degree of reticulin fibrosis (reticulin staining) WHO grade 0-3, if collected as 
standard of care per institutional standards 
o Degree of collagen fibrosis (trichome staining) ELN/international consensus 
grade 0-3, if collected as standard of care per institutional standards 
o Cytogenetics and MDS/AML FISH panel: can be performed if collected as 
standard of care per institutional standards 
o Flow cytometry: can be performed if collected as standard of care per 
institutional standards 
o Central lab aspirate as described in the central lab manual located in the separate 
Study Operations Manual 
 
• 
Symptom Score: Symptom score assessment using a modified MPN-SAF a tool developed by Dr. 
Ruben Mesa to assess total symptom score35. A simplified version is based on the 10 most common 
symptoms associated with MPNs. The total score is the sum of each symptom scored on a 0 to 10 scale 
(0 describes no symptoms and 10 is maximal symptoms). The maximum total score is 100. If subject 
does not circle a line within the survey (skipped question), the data is considered missing and then the 
denominator of total symptom score will be changed to the total number of questions answered. If more 
than one value is circled by the subject then values will be averaged and entered as a single value.  
 
• 
Adverse Event assessments: Toxicities and adverse experiences will be assessed at each visit using 
the NCI Common Toxicity Criteria for Adverse Events 4.0.  See Appendix F for grading of the most 
common adverse events and side effects with ruxolitinib. Unexpected grade 3 or 4 adverse events 
(according to CTCAE term (AE description)) categorized as definitely or possibly attributed to 
ruxolitnib 
will 
also 
be 
recorded 
and 
reported 
as 
indicated 
in 
section 
7. 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 
 
 
All AEs grade 3 and greater and all SAEs, regardless of grade, will be recorded in the CRF.  
 
• 
Central  Samples: A clinical specimen is sent via overnight shipping to the main site (OHSU) at the 
following time points:  
 
For detailed instructions on collection and shipping refer to the Lab Manual located in the separate 
Study Operations Manual 
 
 Peripheral Blood (10ml in sodium heparin-coated tubes): Collected at the time points listed in 
the Schedule of event Calendar.  In addition, a sample is sent at the time of confirmed or 
suspected disease progression, if applicable.  
 
 Bone Marrow Aspirate:  5-8 ml in sodium heparin-coated tubes collected at the time of the 
bone marrow evaluations as listed in the schedule of events calendar. In lieu of repeating a 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 30 
 
baseline bone marrow evaluation, slides and hematopathology reports of sufficient quality will 
be accepted for subjects who had a bone marrow exam within 90 days of cycle #1, day one.    
 
 Skin Biopsy (3.5 mm punch biopsy, one time during the entire study):  A skin sample will be 
excised at the site of the bone marrow biopsy incision, preferably collected at baseline. 
However, if a subject does not have a bone marrow biopsy collected at baseline, the skin biopsy 
may be collected beginning of Cycle 7 or at EOT/early termination bone marrow exam.  
 
 
10.6 
Clinical Response 
Clinical Response will be evaluated at the time points listed in the schedule of events calendar:  
 
Table 6: Assessment occurs at every clinical evaluation visit and compared to start of study (day 1, 
cycle 1) evaluation (see Schedule of Events, Section 10.3)§   
Parameter 
Progression 
Stable disease 
Partial response 
Complete 
response 
WBC and ANC, 
blood 
See Table 3 
Less than 50% 
reduction 
>50% reduction 
Normal range 
Morphologic 
evaluation of 
granulocytic pre-
cursors, bone 
marrow 
See Table 3 
No major reduction 
in granulocytic 
hyperplasia (CNL) 
or dyspoiesis 
(aCML) 
>50% reduction in 
granulocytic 
hyperplasia (CNL) 
or granulocytic 
dyspoiesis (aCML) 
No evidence of 
granulocytic 
hyperplasia 
(CNL) or 
dyspoiesis 
(aCML) 
Spleen size 
estimated by 
palpation or 
ultrasound† 
See Table 3 
No change 
> 25% reduction 
Normal spleen 
size 
 
§Some subjects will not perfectly meet all the criteria (WBC/ANC, marrow findings, or spleen size) in any 
one of these categories (CR, PR, SD, or progression).  The coordinating center will confirm each parameter 
separately and will choose the best category that reflects the overall hematologic response based on source 
documentation.  Three or more reviewers (co-PIs) will review a summarized table of these parameters with 
redacted data and also assign the category that best fits the hematologic response in evaluable subjects at 
cycle 7, week 1. The overall consensus and rationale for each response assessment will be documented. 
Subjects not reaching cycle 7, week 1 are considered non-responders unless otherwise indicated. In addition 
to overall response, the change in each parameter (WBC/ANC, marrow findings, or spleen size) at cycle 7, 
week 1 and at end of study compared to baseline will be reported and evaluated separately.  
†In this study, spleen size is estimated in centimeters by ultrasound (longest dimension in the cranio-caudal 
axis) at baseline, cycle 7, week 1 and end of treatment when spleen size must be measure by ultrasound. 
Additional ultrasounds will be performed if disease progression is suspected at any time during the study 
(table 3). 
‡Complete response, partial (CRp) is defined as responses that meet CR criteria as outlined in this table 
but platelet counts remain below the laboratory’s normal range. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 31 
 
10.7 Schedule of Events   
Please note that this is the mandatory (minimum) schedule of events required for data collection in this 
study in tables.  In most cases, patients will require additional laboratory or clinical evaluations as part of 
the patients’ standard of care.   
 
 
Table 7: Screening, Baseline, and Cycles 1 through 3 
Visit or Cycle # 
Screening/Baseline 
C1 
C2 
C3 
Cycle Week 
1 
2 
3 
4 
1 
3 
1 
3 
Study Windows 
Within 4 weeks 
of Cycle 1, Day 1 
+/- 7 days 
(every effort should be made 
to adhere to actual target 
dates) 
Consent 
X 
 
 
 
 
 
 
 
 
Study registration 
X 
 
 
 
 
 
 
 
 
Study Drug Ruxolitinib dispensation PO 
 
X 
 
 
 
X 
 
X 
 
Study Drug Ruxolitinib administration PO 
 
X-DAILY DOSING 
Pregnancy Test- Urine  (if applicable) 
X 
 
 
 
 
 
 
 
 
Physical Exam, medical history, ECOG, 
IPSS 
X 
X 
 
 
 
X 
 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
 
 
X 
 
X 
 
Vital Signs (BP, HR, RR, O2 Sat, Temp) 
X 
X 
 
 
 
X 
 
X 
 
CBC w/ extended differential1 
X 
X X X X X X X X 
Coagulation Panel: INR/PT and aPTT 
X 
 
 
 
 
 
 
 
 
Chemistry panel with LDH and Uric Acid 
X 
X X X X X X X X 
Spleen Measurement- Ultrasound 
X 
 
 
 
 
 
 
 
 
Bone marrow Exam 
X2 
 
 
 
 
 
 
 
 
Central Lab: Research Bone marrow 
Aspirate Sample3 
X2 
 
 
 
 
 
 
 
 
Central Lab: Research Blood sample3 
X 
X 
 
 
 
 
 
X 
 
Central Lab: Research Skin Punch Biopsy 
Sample at time of Bone marrow Biopsy 
(performed only once during the entire 
study)4 
X4 
 
 
 
 
 
 
 
 
QOL Questionnaire- MPN-SAF 
X 
 
 
 
 
 
 
X 
 
AE assessment 
 
X X X X X X X X 
 
1The exact values of the extended differential profile is per local institutional standard of care. 
2A bone marrow evaluation completed within 90 days prior to Cycle 1, Day 1 may be used as the 
screening/baseline evaluation. 
3Please send blood and marrow samples also at time of confirmed disease progression. 
4If skin punch biopsy was not done at the screening/baseline period the sample may be collected at the time of the 
bone marrow evaluation at Cycle 7, early termination, or end of treatment. 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 32 
 
Table 8: On Study Treatment, Cycles 4 through 12 
Cycle # 
C4 
C5 
C6 
C7 
C8 
C9 
C10 
C11 
C12 
Cycle Week 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Study Windows 
+/- 7 days 
(every effort should be made to adhere to actual 
target dates) 
Study Drug Ruxolitinib dispensation PO 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study Drug Ruxolitinib administration PO 
X-DAILY DOSING 
Physical Exam, medical history, ECOG, 
IPSS 
 
X 
 
X 
 
X 
 
X 
 
Weight 
 
X 
 
X 
 
X 
 
X 
 
Vital Signs (BP, HR, RR, O2 Sat, Temp) 
 
X 
 
X 
 
X 
 
X 
 
CBC w/ extended differential1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation Panel: INR/PT and aPTT 
 
 
 
X 
 
 
 
 
 
Chemistry panel with LDH and Uric Acid 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Spleen Measurement- Ultrasound 
 
 
 
X 
 
 
 
 
 
Bone marrow Exam 
 
 
 
X2 
 
 
 
 
 
Central Lab: Research Bone marrow 
Aspirate Sample2, 3 
 
 
 
X 
 
 
 
 
 
Central Lab: Research Blood sample3 
 
 
 
X 
 
 
 
 
 
QOL Questionnaire- MPN-SAF 
 
 
 
X 
 
 
 
 
 
AE assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
1The exact values of the extended differential profile is per local institutional standard of care. 
2If skin punch biopsy was not done at the screening/baseline period the sample may be collected at the time of this 
bone marrow evaluation. Performed only once during the entire study. 
3Please send blood and marrow samples also at time of confirmed disease progression. 
 
 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 33 
 
Table 9: On Study Treatment, Cycles 13 through 241 
Cycle # 
C 
13 
C 
14 
C 
15 
C 
16 
C 
17 
C 
18 
C 
19 
C 
20 
C 
21 
C 
22 
C 
23 
C 
241 
Cycle Week 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Study Windows 
+/- 7 days 
(every effort should be made to adhere to actual  
target dates) 
Study Drug Ruxolitinib dispensation PO 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study Drug Ruxolitinib administration 
PO 
X-DAILY DOSING 
Physical Exam, medical history, ECOG, 
IPSS 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Weight 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Vital Signs (BP, HR, RR, O2 Sat, Temp) 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
CBC w/ extended differential1,2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation Panel: INR/PT and aPTT1 
 
 
 
 
 
 
X 
 
 
 
 
 
Chemistry panel with LDH and Uric 
Acid1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Spleen Measurement- Ultrasound 
 
 
 
 
 
 
 
 
 
 
 
 
Bone marrow Exam 
 
 
 
 
 
 
 
 
 
 
 
 
Central Lab: Research Bone marrow 
Aspirate Sample3 
 
 
 
 
 
 
 
 
 
 
 
 
Central Lab: Research Blood sample3 
X 
 
 
 
 
 
X 
 
 
 
 
 
QOL Questionnaire- MPN-SAF 
X 
 
 
 
 
 
X 
 
 
 
 
 
AE assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
1If a patient continues on study drug past 24 cycles, standard of care visits and standard of care labs will be collected 
every 8 weeks.  Research data will be collected for the extension period.   
2The exact values of the extended differential profile is per local institutional standard of care. 
 3Please send blood and marrow samples also at time of confirmed disease progression. 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 34 
 
Table 10: Early termination, End of Treatment, and End of Study Visits 
Visit 
Early termination (ET) 
or 
End of treatment (EOT) 
End of study 
safety visit 
Cycle Week 
Study Windows 
Within 14 days of ET 
or 
During week 4 of Cycle 
241 for EOT 
Within 4-6 weeks 
after last dose of 
study drug 
Physical Exam, medical history, ECOG, IPSS 
X 
X 
Height 
 
 
Weight 
X 
X 
Vital Signs (BP, HR, RR, O2 Sat, Temp) 
X 
X 
CBC w/ extended differential1, 2 
X 
X 
Coagulation Panel: INR/PT and aPTT1 
X 
 
Chemistry panel with LDH and Uric Acid1 
X 
X 
Spleen Measurement- Ultrasound 
X 
 
Bone marrow Exam 
X3 
 
Central Lab: Research Bone marrow Aspirate 
Sample3, 4 
X 
 
Central Lab: Research Blood sample4 
X 
 
QOL Questionnaire- MPN-SAF 
X 
 
AE assessment 
X 
X 
 
1If a patient continues on study drug past 24 cycles, subjects will be evaluated for EOT within 2 weeks after 
stopping study drug. 
2The exact values of the extended differential profile is per local institutional standard of care. 
3If skin punch biopsy was not done at the screening/baseline period the sample may be collected at the time of this 
bone marrow evaluation. Performed only once during the entire study. 
4Please send blood and marrow samples also at time of confirmed disease progression. 
 
 
 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 35 
 
MEASUREMENT OF EFFECT 
10.6 Antitumor Effect – Solid Tumors 
Not applicable. 
10.7 Antitumor Effect – Hematologic Tumors 
To measure the antitumor effects of ruxolitinib on CNL or aCML cells, subjects’ white blood cell count 
and absolute neutrophil count will be determined according to the suggested schedule. All of these 
laboratory parameters are expected to be elevated above the standard cut-off for normal control patients. 
The mutant CSF3R allele burden is expected to correlate with tumor burden. 
10.8 Other Response Parameters 
Other response parameters measured include durability of responses, clinical outcome, effects on spleen 
size, and change in total symptom score modified MPN-SAF. 
11 DATA REPORTING/REGULATORY REQUIREMENTS 
11.1 Data Collection and Storage 
Information for each participant will be collected and entered directly into an existing electronic relational 
database. Each site will be responsible for entry of data for patients accrued at that site with all correlative 
data entered by personnel at OHSU, as detailed below. 
 
Medidata Rave, the database that will be used for this trial, was built to house voluminous, diverse data sets 
in a three-dimensional, relational setting whereby all information for a given patient can be viewed and 
correlated with all other pieces of information. This database was launched in October 2011. It is a web-
based interface that references data, which is stored on a secure server such that all information collected 
for any patient can be traced through a hierarchy to show the exact lineage of that information stream. In 
addition, a sophisticated query/report function allows for complex analyses of data that has been collected 
and can thus facilitate integration of diverse data types. This database is supported by a web-portal login, 
and team members currently teams at all trial sites will have login credentials and have been trained in 
procedures for entering, accessing and storing data. This will facilitate information being stored in a unified 
format and location, which will be important for the long-distance collaborations of this trial. 
 
This database utilizes a tiered user format whereby each user is defined based on access to read/edit each 
field as well as privileges of viewing protected health information (PHI). Since every data field is strictly 
defined as to whether PHI is present in that field, users lacking PHI privileges will be completely shielded 
from viewing such information. In addition, all information is stored on an encrypted server and access to 
the database is password protected. Finally, this database undergoes a rigorous back-up and audit trail such 
that information is never in danger of being permanently lost. Hence, the security and integrity of this 
database far surpasses requirements for data storage. 
 
Clinical and demographic information about each patient (i.e. gender, race, ethnicity, date of birth, white 
blood cell count, extended differentials, karyotype/cytogenetics, etc.) will be entered directly into this 
database by each site at which a new patient is enrolled onto the trial. Data from correlative studies will be 
entered by laboratory personnel at OHSU.  
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 36 
 
11.2 Quality assurance will be conducted as outlined in section 12.7 under data safety and 
monitoring. Data, including PHI, will be exchanged with Incyte through a secure portal. PHI 
is limited to date of birth and disease diagnosis. No further patient identifiers will be 
included. Multicenter Guidelines 
This protocol will adhere to the guidelines of the OHSU Knight Multi-Center Investigator Initiated Trials 
Coordinating Center Operations Manual http://ozone.ohsu.edu/cancer/sharedres/kctoresdocs.cfm     
 
OHSU Coordinating Center will manage trial data in the following ways:  
• 
Confirm that all sites have received and are using the most recent version of the protocol. 
The protocol must not be rewritten modified by anyone other than the OHSU Knight 
Principal Investigator. Documentation of the version that was sent to the site must be kept 
in the regulatory binders.  
• 
Confirm that the protocol and informed consent form have local IRB approval at each site 
prior to registration of the first subject. Documentation of IRB approval from other sites 
for continuing review must be submitted and kept in the binder.  
• 
Provide centralized subject registration in the clinical research management system 
(eCRIS) 
• 
Ensure collection and review of applicable source documents and case report by the OHSU 
PI to ensure protocol compliance 
• 
Maintain documentation for all SAE reports and submit a summary of all AE, SAE and 
unanticipated problems (UP) to the Knight DSMP 
• 
Prepare quarterly summary reports of SAEs and UPs from all sites 
• 
Ensure that relevant IRB correspondence and study status changes are communicated to all 
participating sites within five business days. Any changes that affect patient safety of study 
enrollments will be communicated immediately 
• 
Submit documentation to the FDA such as protocol amendments, annual reports, SAE 
reports for unexpected, fatal or life-threatening events that are associated with the use of 
the study drug 
Participating sites must submit regulatory documents including, but not limited to the following:  
• 
Current CV (signed and dated) for each investigator 
• 
Current medical license number for physician investigators 
• 
Current signed FDA Form 1572 
• 
Certificate of completion of institution-required human subject training course, the NIH 
online training in the protection of human research subjects or other appropriate training 
• 
Documentation of institutional Conflict of Interest 
• 
IRB approved site-specific ICF (must be reviewed and approved by OHSU PI and study 
team prior to submission to the local IRB 
• 
All IRB approved documents and approval memos 
• 
Delegation log 
• 
Data Safety and Monitoring Plan (DSMP) 
• 
Completed Case Report Forms within 10 business days of study visit 
11.3 Protocol Review 
The protocol and informed consent form for this study must be reviewed and approved in writing by the 
OHSU Knight Cancer Institute Clinical Research Review Committee (CRRC) and the appropriate 
Institutional Review Board (IRB) prior to any subject being consented on this study.  All sites must have 
IRB approval of protocol by the IRB of record before consenting any subjects. 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 37 
 
11.4 Informed Consent 
Written informed consent will be obtained from all subjects, or the legally authorized representative of the 
subject, participating in this trial, as stated in the Informed Consent section of the case of Federal 
Regulations, Title 21, Part 50.  If a subject’s signature cannot be obtained, and for all subjects under the 
age of 18, the investigator must ensure that the informed consent is signed by the subject’s legally 
authorized representative.  Documentation of the consent process and a copy of the signed consent shall be 
maintained in the subject’s medical record.  All sites must have IRB approval of ICF by the IRB of records 
before consenting any subjects. 
11.5 Changes to Protocol  
Any modification of this protocol must be documented in the form of a protocol revision or amendment 
signed by the principal investigator and approved by the CRRC and IRB, before the revision or amendment 
may be implemented.  The only circumstance in which the amendment may be initiated without regulatory 
approval is for a change necessary to eliminate an apparent and immediate hazard to the subject.  In that 
event, the investigator must notify the CRRC and IRB in writing within 10 working days after the 
implementation. Investigators holding the IND must notify FDA of substantive changes to the protocol.  
Participating site must submit proposed changes to protocol to the OHSU Coordinating Center for review 
and endorsement before participating site may implement changes.  
11.6 Maintenance of Records 
Records and documents pertaining to the conduct of this study, source documents, consent forms, laboratory 
test results and medication inventory records, must be retained by the investigator for a period of 2 years 
following the date a marketing application is approved for the drug for the indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for such indicate, until 
2 years after the investigation is discontinued and FDA is notified.  If the investigator relocates or for any 
reason is unable to retain the records, the study records must be transferred to an agreed upon designee, 
such as another institution, another investigator, or to OHSU Knight Cancer Institute Clinical Trials Office.  
Records must be maintained according to sponsor or FDA requirements.  
11.7 OHSU IRB Reporting of Unanticipated Problems and Adverse Events 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 (Adverse 
Events: List and Reporting Requirements). 
11.8 OHSU Knight Cancer Institute Data and Safety Monitoring Plan 
In addition to complete study and pharmacy files, complete records must be maintained  on each subject 
treated on this protocol.  OHSU Knight Cancer Institute, through the auditing function of the Knight Data 
and Safety Monitoring Committee, is responsible for ensuring that all member investigators and affiliate 
investigators conduct clinical research studies in compliance with local IRB standards, FDA regulations 
and NIH policies and in accordance with the Data and Safety Monitoring Plan policies and procedures: 
http://ozone.ohsu.edu/cancer/sharedres/kctoresdocs.cfm  
 
 
 
Locally initiated studies will be audited by OHSU Knight Data and Safety Monitoring Committee Auditor.  
Newly approved studies may be audited any time after enrollment has been initiated.  Each OHSU Knight 
approved treatment protocol will be audited on an annual basis in accordance with the Knight Data and 
Safety Monitoring Plan.  The OHSU Coordinating Center will audit records maintained at all participating 
centers and if necessary, visit the center to review records and provide training. 
 
It is the responsibility of each participating site’s principal investigator to ensure that the  study 
is 
conducted in compliance with local IRB standards, FDA regulations, and NIH  
policies. It is also the 
responsibility of each site’s principal investigator to ensure that quality assurance audits at their site are 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 38 
 
conducted according to their institution’s policies and procedures. The quality assurance audit process 
provides assurance that reported data accurately reflects the data in the primary subject record. 
 
11.9 Inclusion of Women, Minorities and Children 
11.9.1 Inclusion of Women and Minorities 
No OHSU Knight Cancer Institute study will focus on any particular gender, racial or 
ethnic subset. No subject will be excluded from the study on the basis of gender, racial or 
ethnic origin. Male, female and minority volunteers will be recruited for this study from 
the general population and approximately 50% men and 50% women will be studied. The 
projected gender, racial, and ethnic composition of the study will represent that of the state 
of Oregon. 
 
Table 11: Population Demographics - Oregon (%) 
 
Table 12: Projected Accrual for the Present Study 
Ethnic Category 
Sex/Gender 
Females 
Males 
Unknown 
Total 
Hispanic or Latino 
3 
3 
0-1 
6 
Not Hispanic or Latino 
22 
22 
0-1 
44 
Unknown 
0-1 
0-1 
0-1 
0-1 
Ethnic Category: Total of all subjects* 
25 
25 
0-1 
50* 
Racial Category 
 
American Indian or Alaskan Native 
0-1 
0-1 
0-1 
0-1 
Ethnic Category 
Sex/Gender 
Females 
Males 
Total 
Hispanic or Latino 
5.9 
5.8 
11.7 
Not Hispanic or Latino 
44.5 
43.8 
88.3 
Ethnic Category: Total of all subjects* 
50.4 
49.3 
100* 
Racial Category 
 
American Indian or Alaskan Native 
0.7 
0.7 
1.4 
Asian 
1.9 
1.8 
3.7 
Black or African American 
0.9 
0.9 
1.8 
Native Hawaiian or other Pacific Islander 
0.2 
0.1 
0.3 
White 
42.1 
41.5 
83.6 
More than one race 
1.9 
1.9 
3.8 
Unknown/Other 
2.7 
2.6 
5.3 
Racial Category: Total of all subjects* 
50.4 
49.5 
100* 
TOTALS 
50.4 
49.6 
100* 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 39 
 
Ethnic Category 
Sex/Gender 
Females 
Males 
Unknown 
Total 
Asian 
1 
1 
0-1 
2 
Black or African American 
0-1 
0-1 
0-1 
1 
Native Hawaiian or other Pacific Islander 
0-1 
0-1 
0-1 
0-1 
White 
21 
21 
0-1 
42 
More than one race 
1 
1 
0-1 
2 
Unknown 
1 
1 
0-1 
3 
Racial Category: Total of all subjects* 
25 
25 
0-1 
50* 
 
Source:   Adapted from U.S. Census Bureau, 2010    *Totals may not equal 100 due to rounding.                 
11.9.2 Inclusion of Children 
In accordance with NIH guidelines on the inclusion of children as participants in research involving 
human subjects, children under the age of 18 years must be included in all human subjects’ research, 
conducted or supported by the NIH, unless there are clear and compelling reasons not to include 
them. Therefore, proposals for research involving human subjects must include a description of 
plans for the inclusion of children.  This protocol does not include children for the following reason 
because the number of children with this type of cancer is limited; therefore, children are excluded 
from this study but will be eligible for future pediatric trials with this study agent. 
12 STATISTICAL CONSIDERATIONS 
12.1 Study Design 
 
 
 
This is an open label single-arm phase II clinical trial of ruxolitinib in patients with CNL and aCML. The 
study is comprised of 4 stages: 
1) Screening: up to 4 weeks. 
2) Baseline: up to 2 weeks. 
3) Treatment: up to 96 weeks(extended if benefit to the patient).  
4) Follow-up: and end of treatment visit will occur within 2 weeks of the last dose of ruxolitinib.  An 
end of study visit will occur 4-6 weeks after the last dose of ruxolitinib while on study. 
12.2 Primary and Secondary Endpoints 
The CSF3R mutations represent a biologically unifying feature of CNL and atypical CML and define a new 
molecular subset of hematologic cancers.15  CSF3R has been shown to signal through downstream SRC 
family and JAK-kinase pathways.  The two types of CSF3R mutations may have differential susceptibility 
to classes of tyrosine kinase inhibitors, with CSF3R truncation mutations showing activation of SRC family-
TNK2 kinase signaling and sensitivity to dasatinib, and CSF3R membrane proximal mutations showing 
preferential activation of the JAK signaling pathway.  However, these are based on in vitro studies and we 
predict that the majority of CNL and atypical CML will have some degree of hematologic response with 
ruxolitinib treatment.  Our observation that a patient with membrane proximal mutation had an excellent 
clinical response to the JAK inhibitor ruxolitinib, resulting in a marked decrease in the numbers of white 
cells and neutrophils and an increased platelet count, constitutes a proof of concept. Although anecdotal, 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 40 
 
this observation provides an impetus for further investigation of tyrosine kinase inhibitors for the treatment 
of patients with CNL and atypical CML.15 
 
 
Primary Endpoints: 
 
The primary objective of this study is to determine the proportion of subjects with a hematologic response 
to ruxolitinib (PR, CR, CRp, as defined in Table 6).  The primary endpoint is the indicator variable of 
whether a patient has achieved.  
 
A subject is defined as being responsive if he or she has achieved PR, CR, or CRp, determined at 
the clinical and laboratory evaluations performed at either the beginning of cycle #7 and/or at the 
end of treatment visit compare to start of study (day 1, cycle 1). 
 
A subject is defined as a non-responder if he or she does not reach cycle 7, week 1 unless otherwise 
specified. 
 
Secondary Endpoints: 
 
We will evaluate safety endpoints, including: 
 
The indicator variable for any hematologic grade III or IV adverse effects for thrombocytopenia, 
anemia, and neutropenia at any time point. 
 
The indicator variable for any grade III or IV adverse events or any effects/toxicities directly 
attributed to study drug requiring permanent cessation of drug (refer to Appendix F). 
 
We will evaluate these other endpoints, including: 
 
The indicator variable for whether a patient has achieved clinical responses of PR or better at the 
clinical and laboratory evaluations performed at the beginning of cycle #7 This will be used to 
compute the proportion of such patients among all patients who carry a mutant CSF3R and have a 
more than 25% reduction in mutant CSF3R allele burden with ruxolitinib therapy compare to start 
of study (day 1, cycle 1).  
 
The indicator variable for drop-off and the time of drop-off since treatment. 
 
The indicator variable of dropping off before cycle 3. 
 
The indicator variable of dropping off between cycle 3 and 6. 
 
The indicator variable that subjects has reached cycle 7. 
 
Maximum clinical responses 
 
Duration of maximum clinical responses.  
 
Reduction of spleen size evaluated by ultrasound at the beginning of cycle #7 compare to start of 
study (day 1, cycle 1). 
 
Reduction of total symptom score as measured by a modified MPN-SAF at the beginning of cycle 
#7 compare to start of study (day 1, cycle 1). 
 
Overall survival in subjects who complete minimum of 1 dose of study drug.  Verification of status 
(living or deceased) and cause of death will be attempted, by mail or phone call, up to 5 years after 
enrollment in the study. 
 
Clinical benefit and response analysis will be evaluated by applicable IWG criteria Blood. 
2015;125(12):1857-1865  
12.3 Analysis Populations 
Safety and efficacy analysis will be conducted on every patient who consents and takes study drug, 
regardless of how long they stayed on study drug.  The end of treatment and early termination visit (see 
schedule) includes an evaluation of response at that visit.  Reason(s) for going off study will be collected 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 41 
 
on every patient. 
12.4 Statistical Analysis Plan  
Descriptive statistical analysis will be conducted for all primary and secondary endpoints.  In particular, we 
will compute proportions with 95% exact confidence intervals for categorical variables, and report the 
summary statistics (mean, standard deviation, median, interquartile range) for continuous variables.  An 
empirical plot of trend will be made to graphically illustrate the change over time for peripheral blood WBC 
and ANC, CSF3R allele burden, spleen size, and total symptom score. Chi-square tests will be used to 
assess the association between hematologic response and mutant CSF3R type, and “≥ 50% reduction mutant 
CSF3R allele burden”. Odds ratios and the corresponding 95% confidence intervals will be reported.  
Kaplan-Meier methods will be used to illustrate and summarize overall survival in subjects who complete 
the study. 
 
Safety and tolerability will be assessed by monitoring the frequency, duration and severity of adverse 
events, performing physical examinations, collecting vital signs, collecting laboratory data for hematology, 
serum chemistry, and coagulation parameters.  Proportion of subjects with new onset of Grade 4 
thrombocytopenia events, and proportion of subjects with new onset of Grade 3 or higher hemorrhage, as 
measured by CTCAE v 4.03 will be tabulated with summary statistics. The hazard functions of time to 
onset of the above two safety measures will be estimated using life table method. 
 
Clinical Laboratory Tests 
The clinical laboratory data will be analyzed using summary statistics (e.g., means and frequencies), and 
no formal statistical comparisons among the treatments are planned. 
12.5 Sample Size and Power 
This study has an accrual goal of 25 evaluable subjects who reach cycle 7, week 1. Using the criteria that 
has been generally accepted in general oncology practice, we consider the therapy promising if it has an 
estimated 30% or more response rate (including CR, CRp, or PR, defined in Table 6, reference 36).  The 
null hypothesis to be tested is 10% response rate36. CNL and aCML are rare diseases with no established 
standard of care or effective drug therapies.  As a result, there is no best available therapy to compare to.  
Based on Simon’s two-stage Minimax design, a total of 25 subject will achieve 80% power at 5% 
significance level, with an interim look planned upon the available of primary endpoint for the first 15 
evaluable subjects ( i.e., 15 patients have reached the beginning of cycle #7). The trial will be stopped for 
futility if 1 or 0 subjects responded (response is defined as PR or better) for the first 15 subjects.  Under the 
null hypothesis, the probability of stopping the trial early is 0.549. The expected sample size is 19.50 for 
the two-stage design. By the end of the trial (assuming the trial did not get stopped early for futility), if 6 
or more subjects responded (out of a total of 25), then the drug will be claimed as effective.  We expect that 
each site will on average accrue 5 patients over 2 years.  We expect that the majority of subjects will be 
enrolled by year 3.  Considering the drop-off rate of ~ 50%, we may end up accruing 50 subjects for the 
trial (with only 25 evaluable for the primary endpoint).  
12.6 Randomization Method 
Not applicable.  
12.7 Handling of Missing Data 
Every attempt will be made to obtain data at the defined time points as described in the primary and 
secondary endpoints.  The labs or studies outlined in section 10.3, schedule of events, may be completed 
within 7 days of the target week (7 days before or 7 days after).  However, every effort will be made to 
adhere to this schedule as close as possible.   For time points that have no data, we will evaluate whether or 
not the other time points can be used to fulfill the primary and secondary data.  If the data is not sufficient 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 42 
 
to analyze specific endpoints, the subject’s data may be excluded entirely or partially, depending on the 
specific endpoints in question and in consultation with the biostatistician. 
APPENDIX A CRITERIA FOR DIAGNOSIS OF CNL AND aCML 
 
Chronic neutrophilic leukemia 
• 
Peripheral blood  
o 
Leukocytosis ≥25 x 109/L 
o 
Segmented neutrophils and bands >80% of leukocytes 
o 
Immature granulocytes <10% of leukocytes* 
o 
Myeloblasts <1% of leukocytes 
• 
Bone marrow 
o 
Hypercellular bone marrow 
o 
Increased number and percentage of neutrophilic granulocytes 
o 
Nucleated marrow cells, with <5% myeloblasts 
o 
Normal neutrophilic maturation pattern   
• 
No Philadelphia chromosome or bcr/abl fusion gene  
• 
No other cause for neutrophilia 
o 
No infectious or inflammatory process 
o 
No evidence of another myeloproliferative disease 
o 
No evidence of a myelodysplastic or myelodysplatic, myeloproliferative disease 
o 
No evidence of a tumor or, if present, myeloid cells must show clonality  
 
Note: For this study, leukocytosis should persist for at least 2 months, either by historical laboratory 
results or subsequent follow-up laboratory results. 
 
 
Atypical chronic myeloid leukemia 
• 
Peripheral blood  
o WBC count > 13 x 109/L 
o >10% neutrophil precursors (promyelocytes, myelocytes, metamyelocytes*), basophils 
<2% of leukocytes, monocytes <10% of leukocytes, blasts <20% of nucleated cells  
• 
Bone marrow 
o Hypercellular marrow with granulocytic proliferation and dysplasia** 
o Blasts <20% of nucleated cells 
• 
No BCR/ABL1 gene fusion, no rearrangement of PDGFRA, PDGRB or FGFR1 
 
Note: For this study, leukocytosis should persist for at least 2 months, either by historical laboratory 
results or subsequent follow-up laboratory results. 
 
 
 
* Day to day fluctuation of immature granulocytes frequently occurs in patients with CNL or aCML, 
therefore the intent is for the patient to meet diagnostic criteria based on their typical % immature 
granulocytes. 
 
**Patients who don’t meet the dysplasia or immature granulocytes criteria are eligible if they have 
oncogenic CSF3R mutations. 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 43 
 
APPENDIX B SUMMARY OF STARTING DOSE AND DOSE ADJUSTMENTS FROM 
PRESCRIBING INFORMATION FOR RUXOLITINIB 
 
The information in this appendix is for reference only from the prescribing information. 
See Table 2 in the main protocol for dosing SUGGESTIONS for this clinical trial.  
 
Proposed ruxolitinib Starting Doses 
 
 
 
 
 
 
 
Maximum Restarting Doses for ruxolitinib After Safety Interruption 
 
For the most current prescribing information, go to: 
http://www.incyte.com/sites/default/files/Jakafi_PI.pdf 
 
 
 
 
 
 
 
 
 
 
 
 
Platelet Count 
Starting Dose 
Greater than 200 X 109/L 
20 mg orally twice daily 
100 X 109/L to 200 X 109/L 
15 mg orally twice daily 
Current Platelet Count 
Maximum Dose When Restarting  ruxolitinib 
Treatment 
Greater than or equal to 125 X 109/L 
20 mg twice daily 
100 to less than 125 X 109/L 
15 mg twice daily 
75 to less than 100 X 109/L 
10 mg twice daily for at least 2 weeks; if stable, may 
increase to 15 mg twice daily 
50 to less than 75 X 109/L 
5 mg twice daily for at least 2 weeks; if stable, may 
increase to 10 mg twice daily 
Less than 50 X 109/L 
Continue hold 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 44 
 
APPENDIX C ECOG PERFORMANCE STATUS* 
 
Grade ECOG 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
2 
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up 
and about more than 50% of waking hours 
3 
Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours 
4 
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair 
5 
Dead 
* As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.  
 
 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 45 
 
APPENDIX D TABLE OF MODERATE AND POTENT CYP3A4 INHIBITORS  
 
Use of all CYP3A4 inhibitors is discouraged as they may have effects on ruxolitinib levels, and 
alternative therapies should be sought if available.   
 
Strong Inhibitors 
Moderate Inhibitors 
Weak Inhibitors 
All other inhibitors 
indinavir1 
nelfinavir1 
ritonavir1 
saquinavir1 
clarithromycin2 
itraconazole2 
ketoconazole2 
nefazodone2 
posaconazole2 
voriconazole2 
telithromycin2 
aprepitant2 
erythromycin2 
fluconazole2 
grapefruit juice2 
verapamil2 
diltiazem2 
 
cimetidine 
 
amiodarone 
chloramphenicol 
delaviridine 
diethyl-
dithiocarbamate 
fluvoxamine 
gestodene 
imatinib 
mibefradil 
mifepristone 
norfloxacin 
norfluoxetine 
starfruit 
1 Subjects receiving these medications should not be allowed in the study as HIV+ patients are excluded. 
2 Close monitoring of platelet counts and dose reductions are required with the addition of moderate to 
potent CYP 3A4 inhibitors.  See Section 6. 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 46 
 
APPENDIX E GRADING OF HEMORRHAGIC EVENTS  
 
 
Grade I 
Grade II 
Grade III 
Grade IV 
Grade V 
Blood and 
lymphatic 
system 
disorders - 
Other, 
specify 
 
Asymptomatic 
or mild 
symptoms; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicated 
 
Moderate; 
minimal, local 
or noninvasive 
intervention 
indicated; 
limiting age 
appropriate 
instrumental 
ADL 
 
Severe or 
medically 
significant but 
not immediately 
life threatening; 
hospitalization 
or prolongation 
of existing 
hospitalization 
indicated; 
disabling; 
limiting self-
care ADL 
Life-
threatening 
consequences;  
urgent 
intervention 
indicated 
 
Death 
 
Refer to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; Published: May 28, 
2009 (v4.03: June 14, 2010).   
 
For the latest version, go to: 
 http://evs.nci.nih.gov/ftp1/CTCAE/About.html 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 47 
 
APPENDIX F ADVERSE EVENTS AND SIDE EFFECTS WITH RUXOLITINIB 
 
Relevant sections from prescribing information provided here.  Adverse events highlighted in BOLD 
will be recorded and summarized based on the indicated cut-off values.  Unexpected grade 3 or 4 
adverse events (according to CTCAE term (AE description)) categorized as definitely or possibly 
attributed to ruxolitnib will also be recorded and reported as indicated in section 7. 
 
5.1 Thrombocytopeniaa, Anemiab, and Neutropeniac Treatment with ruxolitinib can cause 
thrombocytopenia, anemia and neutropenia. [see Dosage and Administration (2.1)]. Thrombocytopenia was 
generally reversible and was usually managed by reducing the dose or temporarily interrupting ruxolitinib. 
Platelet transfusions may be necessary [see Dosage and Administration (2.2), and Adverse Reactions (6.1)]. 
Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi. Severe 
neutropenia (ANC less than 0.5 X 109/L) was generally reversible. Withhold ruxolitinib until recovery 
[see Adverse Reactions (6.1)]. Perform a pre-treatment complete blood count (CBC) and monitor CBCs 
every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. [see Dosage and 
Administration (2.2), and Adverse Reactions (6.1)]. 
 
5.2 Risk of Infectiond Serious bacterial, mycobacterial, fungal and viral infections may occur. Active 
serious infections should have resolved before starting therapy with ruxolitinib. Observe patients receiving 
ruxolitinib for signs and symptoms of infection and initiate appropriate treatment promptly. 
 
a less than 50,000 per microliter 
b less than Hgb 7 g/dL 
c less than ANC 500 cells per microliter 
d requiring hospitalization or intravenous antibiotics 
 
 
 


 
 
 
 
Protocol Version 7: December 7, 2017 
Page 48 
 
APPENDIX G EFFECTIVE CONTRACEPTIVE PRACTICES 
 
For Males Subjects Participating in the Study: 
The following methods have been determined to be more than 99% effective (failure rate less than 1% per 
year, when used consistently and correctly) (Trussell, 2004), by the male subject and his partner and are 
permitted under this protocol: 
 
• 
Complete abstinence from sexual intercourse 
• 
Double barrier methods 
o Condom with spermicide in conjunction with use of an intrauterine device (IUD) 
o Condom with spermicide in conjunction with use of a diaphragm 
• 
Oral, injectable, or implanted contraceptives 
• 
Tubal ligation or vasectomy (surgical sterilization) 
 
 
For Female Subjects Participating in the Study: 
The following methods have been determined to be more than 99% effective (failure rate less than 1% per 
year, when used consistently and correctly) (Trussell, 2004), by the female subject and her partner and are 
permitted under this protocol: 
 
• 
Complete abstinence from sexual intercourse 
• 
Double barrier methods 
o Condom with spermicide in conjunction with use of an IUD 
o Condom with spermicide in conjunction with use of a diaphragm 
• 
Tubal ligation or vasectomy (surgical sterilization) 
• 
Oral, injectable, or implanted contraceptives 
 
Subjects >55 y/o and without menses for at least 3 years are considered in menopause. 


 
 
 
 
Protocol Version 6: July 25, 2017 
Page 49 
 
LIST OF ABBREVIATIONS 
 
The following abbreviations and special terms are used in this study protocol. 
 
Term 
Explanation 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANC 
Absolute neutrophil count 
bid 
Twice daily 
CBC 
Complete blood count 
Cmax 
Maximum observed plasma concentration 
CRF 
Case report form 
CT 
Computed Tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
dL 
Deciliter 
DLT 
Dose limiting Toxicity 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Forms 
ECOG 
Eastern Cooperative Oncology Group 
ET 
Essential throbocythemia 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
IB 
Investigator’s Brochure 
ICF 
Informed consent form 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
INR 
International Normalized Ratio 
IPSS 
International Prognostic Scoring System 
IRB 
Institutional Review Board 
IVRS 
Interactive Voice Response System 
IWG-MRT 
International Working Group for Myelofibrosis Research and Therapy 
JAK 
Janus kinase 
MF 
Myelofibrosis 
MPN-SAF  
Myeloproliferative neoplasm symptom assessment form v2.0 
mg 
Milligram 
MPN 
Myeloproliferative neoplasm 


 
 
 
 
Protocol Version 6: July 25, 2017 
Page 50 
 
MRI 
Magnetic Resonance Imaging 
PD 
Pharmacodynamic 
PET-MF 
Post essential thrombocythemia myelofibrosis 
PGIC 
Patient Global Impression of Change 
PI 
Principal Investigator 
PK 
Pharmacokinetics 
PMF 
Primary Myelofibrosis 
PV 
Polycythemia vera 
PPV-MF 
Post polycythemia vera myelofibrosis 
PR 
Partial remission 
PTT 
Partial Thromboplastin time 
qd 
Once daily 
ruxolitinib 
ruxolitinib phosphate or ruxolitinib phosphate tablets, based on context 
SAE 
Serious adverse event 
STAT 
Signal transduction and activator of transduction 
ULN 
Upper limit of normal 
WBC 
White blood cells 
 


 
 
 
 
Protocol Version 6: July 25, 2017 
Page 51 
 
REFERENCES 
 
1. 
Bain BJ, Brunning RD, Vardiman JW, Thiele J. Chronic neutrophilic leukaemia. In: 
Swerdlow SH, Campo E, Lee Harris N, et al., eds. WHO Classification of Tumors of 
Haematopoietic and Lymphoid Tissues (ed 4th). Lyon: IARC Press; 2008:38-39. 
2. 
Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J. Atypical chronic myeloid 
leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Lee Harris N, et al., eds. WHO 
Classification of Tumors of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon: IARC Press; 
2008:80-81. 
3. 
Froberg MK, Brunning RD, Dorion P, Litz CE, Torlakovic E. Demonstration of clonality 
in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia. 1998;12:623-626. 
4. 
Matano S, Nakamura S, Kobayashi K, Yoshida T, Matsuda T, Sugimoto T. Deletion of the 
long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: cytogenetic findings 
in chronic neutrophilic leukemia. Am J Hematol. 1997;54:72-75. 
5. 
Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic 
characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11:441-444. 
6. 
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 
in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. 
7. 
Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase 
mutation is an infrequent event in both "atypical" myeloproliferative disorders and 
myelodysplastic syndromes. Blood. 2005;106:1207-1209. 
8. 
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to 
constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. 
9. 
Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in 
chronic myeloproliferative disorders. Blood. 2005;106:2162-2168. 
10. 
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in 
myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. 
11. 
Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 
in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 
Cancer Cell. 2005;7:387-397. 
12. 
Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria 
pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell 
neoplasm. Nat Genet. 1996;12:312-314. 
13. 
Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic 
domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have 
mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560-
10564. 
14. 
Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined 
chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the 
literature. Leukemia. 2005;19:313-317. 
15. 
Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic 
neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781-1790. 
16. 
Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 
2010;115:5131-5136. 
17. 
Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased 
apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. 


 
 
 
 
Protocol Version 6: July 25, 2017 
Page 52 
 
Immunity. 1996;5:491-501. 
18. 
Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene 
for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia 
preceded by severe congenital neutropenia. N Engl J Med. 1995; 3:487-493. 
19. 
Dong F, Hoefsloot LH, Schelen AM, et al. Identification of a nonsense mutation in the 
granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad 
Sci U S A. 1994;91:4480-4484. 
20. 
Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe 
congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood. 
2007;109:93-99. 
21. 
Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe 
congenital neutropenia progressing to acute myeloid leukemia. Blood. 2012;119:5071-5077. 
22. 
Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte 
colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute 
myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. J 
Immunol. 2001;167:6447-6452. 
23. 
van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor 
truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave 
suppression of STAT3 intact. Blood. 2004;104:667-674. 
24. 
Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained 
activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital 
neutropenia/acute myeloid leukemia. Blood. 1999;93:447-458. 
25. 
Hermans MH, Ward AC, Antonissen C, Karis A, Lowenberg B, Touw IP. Perturbed 
granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor 
receptor gene associated with severe chronic neutropenia. Blood. 1998;92:32-39. 
26. 
Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in 
severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to 
apoptosis and enhance cell survival. Blood. 2000;95:2132-2137. 
27. 
Mitsui T, Watanabe S, Taniguchi Y, et al. Impaired neutrophil maturation in truncated 
murine G-CSF receptor-transgenic mice. Blood. 2003;101:2990-2995. 
28. 
Corey SJ, Dombrosky-Ferlan PM, Zuo S, et al. Requirement of Src kinase Lyn for 
induction of DNA synthesis by granulocyte colony-stimulating factor. J Biol Chem. 
1998;273:3230-3235. 
29. 
Corey SJ, Burkhardt AL, Bolen JB, Geahlen RL, Tkatch LS, Tweardy DJ. Granulocyte 
colony-stimulating factor receptor signaling involves the formation of a three-component complex 
with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci U S A. 1994;91:4683-4687. 
30. 
Futami M, Zhu QS, Whichard ZL, et al. G-CSF receptor activation of the Src kinase Lyn 
is mediated by Gab2 recruitment of the Shp2 phosphatase. Blood. 2011;118:1077-1086. 
31. 
Zhu QS, Robinson LJ, Roginskaya V, Corey SJ. G-CSF-induced tyrosine phosphorylation 
of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not 
proliferative, responses. Blood. 2004;103:3305-3312. 
32. 
Plo I, Zhang Y, Le Couedic JP, et al. An activating mutation in the CSF3R gene induces a 
hereditary chronic neutrophilia. J Exp Med. 2009;206:1701-1707. 
33. 
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of 
ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807. 


 
 
 
 
Protocol Version 6: July 25, 2017 
Page 53 
 
34. 
Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical 
chronic myeloid leukemia. Nat Genet. 2013;45:18-24. 
35. 
Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom 
Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 
patients. Blood. 2011;118:401-408. 
36.  
Davita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: 
Principles & Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins. 2008: Chapter 
28, Richard Simon.